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1Heroin dependence is increasing in the United
Kingdom. It is a major public health problem
with an elevated risk of illness and of death. It
has high social and criminal costs. The Audit
Commission (2002) noted that the total bill to
the public purse for all drug problems
(including heroin) was between three and four
billion pounds in 2001/02, and the Home Office
estimates that there may be in the region of
200,000 problem heroin users in the UK (Home
Affairs Committee, 2002a).
Providing a medical prescription for
pharmaceutical heroin (diamorphine) to heroin
addicts has been seen in some countries as a way
of solving the ‘heroin problem’ with potential
benefits to the individual addict and to society.
Addiction and dependence describe
compulsive use of a drug. Heroin dependence is
a chronic relapsing condition, meaning that,
although people may be able to stop using the
drug for short periods, they soon start using
again. Treatment often involves substituting –
on a short- or long-term basis – a legal drug for
the illegal drug. The most common substitution
drug for heroin is methadone – a long-acting
synthetic opiate which is prescribed in non-
injectable form. However, despite the benefits of
oral methadone (Ward et al., 1998), there are
people who appear not to want it or benefit
from it. It has been suggested, therefore, that
pure pharmaceutical heroin (diamorphine or
diacetylmorphine) be prescribed to replace the use
of illicit heroin. This proposal remains
controversial.
The current debate
The UK is exceptional internationally because
heroin is included in the range of legally
sanctioned treatments for opiate dependence. In
practice, this treatment option is rarely utilised:
only about 448 heroin users receive heroin on
prescription (Metrebian et al., 2002). Some
people would like to see heroin prescribed to
more people who are dependent on it. But an
increase in prescribing heroin may have benefits
as well as risks. Coming to a judgement on the
merits of prescribing heroin for the treatment of
opiate dependence requires looking at scant
research evidence to determine whether heroin
prescribing is likely to have an advantage over
other treatments for dependence.
1 Introduction: the history of the heroin
prescription debate
The UK is exceptional internationally because heroin is included in the range of legally sanctioned
treatments for opiate dependence.
This chapter:
• outlines the arguments in favour of and against prescribing heroin in the treatment of people who
are dependent on it
• gives a history of heroin prescribing
• shows how the reasons for prescribing heroin have changed from a primary concern to improve
health to a concern to reduce crime.
2Prescribing heroin
Those in favour of prescribing heroin for the
treatment of opiate dependence often point to
the following in support of their case:
• Current treatments – mainly methadone
substitution – are insufficiently attractive
or effective for some heroin addicts.
Prescribing heroin users their drug of
choice might attract more people into
treatment and retain them in treatment
for longer. More heroin users would get
help and there would be fewer untreated
heroin users in the community.
• It may help some people to stop or reduce
their illicit heroin use; this would
undercut the black market in illicit heroin;
and ensure that heroin users can use a
drug of known quality and strength.
• It may help people avoid health problems
(such as overdose) and unsafe injecting
practices that can lead to transmission of
HIV and hepatitis B and C (HBV, HCV).
• It may lead to less acquisitive crime to
support a drug habit and to improved
social functioning (work, housing and
family life).
• It is a first step that may facilitate a
gradual change away from heroin use to
methadone, and from injecting to oral
use.
• Individual heroin users would benefit –
and so would society – by having less
drug-related crime, lower criminal justice
and prison costs, fewer or less visible
drug markets, lower aggregate health-
care costs, and lower social welfare costs.
Those who do not favour the medical
prescription of heroin, or who are more
cautious, often point to the following:
• It might maintain the condition of
dependence by removing the motivation
to stop using or injecting drugs. It might
prolong the time a heroin user is drug
dependent and injecting.
• An accumulating population of patients
receiving a prescription for heroin
prevents others from getting treatment.
• Individuals might suffer adverse health
consequences as a result of continued
heroin injecting (even though the drug is
prescribed), including risk of overdose,
infections, abscesses and blood-borne
viruses, e.g. HIV and HCV.
• Society would have more heroin users
and an increasing burden of ill-health.
• Pharmaceutical heroin is more expensive
than methadone. Society has finite
resources so needs to allocate them
equitably.
• Heroin users presenting for treatment
would come to expect heroin and might
not accept alternatives such as oral
methadone.
• There would be potential for diversion of
prescribed heroin onto the illicit market,
with the danger that new heroin users
would be created.
• It is better to use treatments of known
effectiveness such as methadone.
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Which countries allow the prescription of
heroin to addicts?
Heroin is prescribed in the treatment of opiate
dependence in only a few countries.
In the UK, heroin has been prescribed to
treat opiate dependence since the 1920s. It was
originally adopted to help drug addicts lead
normal lives without needing to purchase illegal
drugs. More recently, the UK government has
proposed the limited expansion of heroin
prescribing because of the potential impact of
such a strategy on reducing crime as well as
improving the health of heroin users.
Scientific trials of heroin treatment have been
completed in Switzerland (Uchtenhagen et al.,
1999) and the Netherlands (van den Brink et al.,
2002). Switzerland has now authorised the
prescription of heroin for opiate dependence.
Since 1998, heroin can be prescribed in the
Netherlands for research purposes.
Scientific trials on the efficacy of heroin
prescribing are planned or are taking place in
Germany, France, Belgium, Spain and Canada
(Fischer et al., 2002). In 1992, Australia
undertook research studies on the feasibility of
prescribing heroin but the proposed trial did not
take place, reputedly because of outside
pressure on the Australian government.
Who now wants to increase heroin
prescribing in the UK?
The Updated Drug Strategy for the UK (Home
Office, 2002) states that the medical prescription
of heroin will be available for all those who
have a clinical need. This policy is part of the
government’s aim to break the cycle of drug
misuse and crime by providing effective
treatment and rehabilitation. In its review of the
government’s drug policy, the Home Affairs
Committee also recommended that a pilot
programme of prescribing heroin be conducted,
targeted in the first instance at chronic heroin
users who are prolific offenders. It also made
recommendations for a trial to look at the
prescription of heroin to addicts with a long
history of addiction who have not yet gained
access to treatment or who are not currently in
treatment (Home Affairs Committee, 2002a, p.
46). It is interesting to note that, in the UK,
prescribing heroin is seen – at least by
government – more as a way of reducing drug-
related crime than as a public health strategy to
reduce the risk of HIV infection or mortality due
to overdose.
There is also support for heroin prescribing
from the Liberal Democratic party. Its Home
Affairs spokesperson Simon Hughes said:
‘Heroin should be available on prescription
because obtaining it through safe outlets is
much safer than forcing addicts back into the
hands of dealers’ (BBC News Online, 2002). The
Association of Chief Police Officers asserted
that:
… there is a compelling case to explore further
the merits of prescribing drugs of addiction to
patients with entrenched dependency problems
who have not responded to other forms of
therapy ... This should include the wider use of
heroin within a menu of treatments.
(Association of Chief Police Officers, 2002,
pp. 1–2)
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History of prescribing heroin
Worldwide, drug treatments have been
influenced by international agreements to
control drugs, and by changing ideas about the
nature of the ‘heroin problem’ and how to solve
it. As we have already seen, some see
prescribing heroin as a way to reduce the
problem of drug-related crime and others
emphasise the advantages of heroin prescribing
as a way of reducing public health problems
(e.g. overdoses, infectious diseases).
The international control of heroin began in
1909 in Shanghai at a special commission
convened by the USA. A convention signed in
The Hague in 1912 limited the manufacture,
distribution and use of heroin to medical use.
This was as a result of the growing opium trade
(heroin is an opiate derived from opium), which
had come under increased criticism because of
the increasing numbers of individuals addicted
to heroin. As a result, in the USA, the 1914
Harrison Narcotic Act restricted the use of
opiates to legitimate medical purposes and, by
1919, doctors could be prosecuted for
prescribing opiates to addicts. In the UK, the
Dangerous Drugs Act of 1920 restricted the
supply of morphine and heroin to registered
medical practitioners for the purpose of medical
treatment. In 1956, with the Narcotic Drug
Control Act, the medical use of heroin was
completely withdrawn in the USA and many
other countries (although hospitals were
allowed to continue using existing stocks of
heroin).
Many countries believe (erroneously) that
the international drug conventions prohibit the
use of heroin in medical treatment.
Furthermore, the International Narcotics
Control Board (INCB) has exerted great
pressure on countries to cease prescribing
heroin for any medical purpose. Nevertheless, a
few countries, including the UK, Belgium, the
Netherlands, Iceland, Malta, Canada and
Switzerland, continue to use heroin
(diamorphine) for general medical purposes,
mostly in hospital settings (usually for severe
pain relief). Until recently, however, Britain was
the only country that allowed doctors to
prescribe heroin for the treatment of drug
dependence.
Heroin prescribing in the UK
Prescribing heroin and other opiate drugs has
been part of the British response to opiate
dependence since the 1920s. While the USA
chose to criminalise heroin dependency, Britain
chose to medicalise the problem. In the UK, the
reasons for prescribing heroin have changed
over the last 100 years reflecting different
historical contexts and changing perceptions of
‘the problem’ (Hartnoll, 1993).
Chief Superintendent John Issac of Devon
and Cornwall Police told BBC’s Newsnight:
There will always be a debate among
the medical profession about the ethics
of prescribing heroin. But from a police
officer’s point of view, I have to say that
if it reduces crime, reduces the number
of victims, that has to be a very serious
consideration. And I would support it.
(BBC News, 15 January 2002)
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1920s–60s: helping addicts lead normal lives
In the early 1920s, the extent of the opiate
problem in the UK was very small, with few
individuals dependent on morphine and even
fewer on heroin. In 1926, the Rolleston
Committee was convened to consider and
advise as to the circumstances, if any, in which
the prescription of heroin or morphine to
addicts was medically advised. This report
recommended that medical practitioners could
prescribe heroin or morphine to addicts if it
would enable patients to lead useful lives
(Departmental Committee on Morphine and
Heroin Addiction, 1926). Thus, from the late
1920s, it was considered bona fide medical
practice to maintain addicts on their drug of
addiction if other treatments had failed and if
they were able to live ‘normal and useful lives’
when given a regular, stable dose but were
unable to do so when the supply of the drug
was withdrawn (Departmental Committee on
Morphine and Heroin Addiction, 1926). Until
1968, any doctor could prescribe heroin or other
opiate drugs in the treatment of opiate
dependence. The majority of doctors who
prescribed heroin were general practitioners.
This approach worked reasonably well with
the addict population of the time, most of who
were in the medical and nursing professions
and who became addicted because they had
access to opiates; others were individuals who
had become addicted in the course of medical
treatment (known as therapeutic or iatrogenic
addicts).
Mid-1960s: prescribing to contain the black
market
In 1961, the Brain Committee was established
(Interdepartmental Committee on Drug
Addiction) to consider whether the prescribing
The 1926 recommendations
Circumstances in which morphine or heroin may legitimately be administered to addicts:
There are two groups of persons suffering from addiction to whom the administration of morphine
or heroin may be regarded as legitimate medical treatment, namely:
a Those who are undergoing treatment for cure of addiction by the gradual reduction method;
b Persons for whom, after every effort has been made for the cure of addiction, the drug cannot be
completely withdrawn, either because:
i complete withdrawal produces serious symptoms which cannot be satisfactorily treated
under the ordinary conditions of private practice, or where:
ii a patient, who while capable of leading a useful and fairly normal life so long as he takes a
certain non-progressive quantity, usually small, of the drug of addiction, ceases to be able to
do so when the regular allowance is withdrawn.
(Departmental Committee on Morphine and Heroin Addiction, 1926, p. 33, quoted in
Spear, 2002)
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policy (based on Rolleston) should be revised
and whether there was a medical need to
provide special treatment outside the resources
already available. It concluded that the drug
problem was still small. The Committee saw no
reason for any changes in existing practice or
procedures.
However, at the beginning of the 1960s, there
was a sharp increase in the numbers of heroin
users. These were ‘hedonistic’ heroin users –
individuals using heroin initially ‘recreationally’
and for pleasure, and associated with a ‘deviant’
or ‘underground’ culture. The doctors who
prescribed heroin thought they were helping to
contain an illicit market in heroin. They little
realised that some of the heroin that they were
prescribing was being sold and therefore they,
by prescribing heroin, were helping the black
market to expand. Some heroin users received
very large prescriptions for heroin and were
selling some of it.
Concerns about the increase in numbers of
known heroin users led to the establishment of
the Second Brain Committee. The Committee
(Interdepartmental Committee on Drug
Addiction, 1965) blamed the increase in heroin
use on the doctors who were overly generous in
their prescribing, stating that ‘the majority
source of supply has been the activity of a very
few doctors who have prescribed excessively for
addicts’ (Ministry of Health and Scottish Home
and Health Department, 1965). At the time of
report, several doctors were prescribing heroin
and cocaine in very large quantities. The Brain
Committee recommended that restrictions
should apply to the prescribing of heroin and
that ‘treatment centres be set up, mainly in
London and might form part of a psychiatric
hospital or the psychiatric wing of a general
hospital’. In effect, the report recommended
that, to control the problem, the right to
prescribe heroin for the treatment of addiction
should be restricted to psychiatrists working at
special drug clinics. This report informed new
legislation.
In 1967, the Dangerous Drug Act restricted
the prescribing of heroin and cocaine in the
treatment of addiction to doctors holding
licences from the Home Office. Prescribing
heroin in the treatment of other medical
conditions was unaffected. In 1968, new
specialist drug dependency units (DDUs) were
established by the Ministry of Health – mainly
in London. The licensed doctors were mostly
NHS psychiatrists in charge of the DDUs – thus
effectively excluding general practitioners from
prescribing heroin for the treatment of opiate
dependence.
One reason for prescribing heroin – given by
the Ministry of Health at that time and some of
the doctors in the clinics – was to contain the
spread of the ‘epidemic’. Doctors tried to
prescribe just enough to tempt people into
Medical care and social control
The establishment of the drug clinics in
1968 brought to the fore that doctors were
now working both for the patient and on
behalf of society to control a social
problem. The tension between treatment
and care on the one hand and social
control on the other has since been a
continuing feature of drug policy and
medicine’s involvement in this field. It
begs the question of ‘who benefits from
heroin prescribing?’.
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treatment, but not too much because this might
feed the illicit drug market. Some described this
as ‘competitive prescribing’ – doctors competing
against the illicit drug market by maintaining
heroin users on just the right dose. Too much
and they might sell it, too little and they might
turn to the illicit drug market.
1970s: the shift from heroin to methadone, and
from maintenance to abstinence
After 1970, prescribing heroin went out of
favour and doctors at the clinics started to
persuade patients to change to methadone as a
substitute drug.
This shift was influenced by a number of
reasons. These included concerns over the
potential threat of the diversion to the black
market of prescribed heroin, growing optimism
about the positive therapeutic effects of
methadone and its advantages over heroin, and
concerns with the safety of continued injecting
of heroin. Many doctors considered that
prescribing heroin was ‘feeding a habit’ while
prescribing methadone was a ‘medical
treatment’. Steadily accumulating clinic
caseloads of patients maintained long term on
heroin, and drug workers’ disenchantment with
maintaining heroin users on heroin, also
contributed to the shift of opinion. Moreover,
doctors became more interested in abstinence
than maintenance as a treatment goal.
There was little conclusive research evidence
to support this change away from prescribing
heroin and no formal change of drug policy.
Rather, it was as a result of doctors’ decisions
and peer pressure within the medical
profession. Contributing to the support for this
change in treatment were the results of a
randomised controlled trial conducted by
Richard Hartnoll and Martin Mitcheson
(Hartnoll et al., 1980) comparing heroin
maintenance with oral methadone maintenance.
The results of the trial were inconclusive and the
authors’ conclusions cautious.
Hartnoll and Mitcheson found that those
receiving a prescription for heroin tended to
stay in treatment but continued to inject and use
illicit drugs, although in smaller amounts than
before entering treatment. Those receiving oral
methadone went to one extreme or another:
either they stopped using illicit drugs
completely or they continued to be heavily
involved in drugs and dropped out of
treatment.
The results identified advantages and
disadvantages of both treatments. But the
results were interpreted by many to show that
The shift from heroin to methadone, and
from maintenance to abstinence
It [the Hartnoll and Mitcheson
study] has been widely credited with
changing treatment policies in the
newly established Drug Dependence
Units away from heroin maintenance to
policies focused on short-term
methadone prescribing, and towards
abstinence as a goal. It formed the basis
of guidelines on good clinical practice
issued in 1984. This was certainly not
the aim of the researchers. Despite the
authors’ reservations about the results,
the research was taken to show that oral
methadone maintenance treatment was
preferable.
(Berridge and Thom, 1996, p. 25)
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oral methadone was preferable, and that heroin
encouraged continued drug use and led to
steadily accumulating clinic populations. The
research provided a justification for a change
already under way.
This is the only randomised controlled trial
of heroin versus methadone treatment that has
ever been attempted in the UK.
Mid-1980s: control of HIV/AIDS –
maintenance back on the agenda
The advent of HIV/AIDS in the mid- to late-
1980s saw another shift in views on maintenance
prescribing. Methadone maintenance was
increasingly seen as an intervention that could
reduce the harm from injecting drug use. The
main aim became helping injectors change their
behaviour by assisting them to stabilise their
drug use and reduce HIV risk behaviour (e.g. the
sharing of needles and syringes). It was now seen
to be a public health imperative to get heroin
users into treatment and to retain them in
treatment for as long as possible, thus providing
the opportunity to impact on risk behaviours.
But, although maintenance was back on the
agenda, it was mainly with oral methadone
rather than heroin.
Mid-1990s: drugs and crime – prescribing
heroin to reduce crime
More recently, the perception of the problem has
changed again. Problem heroin use is now seen
by the UK government mainly as a drug-related
crime issue.
The policy shift began during the first term
of the Labour government after the 1997 general
election. In his introduction to the White Paper
Tackling Drugs to Build a Better Britain, the Prime
Minister Tony Blair wrote of the need to ‘break
once and for all the vicious cycle of drugs and
crime which wrecks lives and threatens
communities’ (Home Office, 1998, p. 1). The
UK’s first Anti Drug Coordinator (or ‘drug
czar’), appointed in 1997, echoed the theme in
his First Annual Report and National Plan – the
aim of which was ‘to rid our society of the cycle
of drugs and crime’.
The policy had several premises: crime is a
key concern for communities – and a key issue
for the government; a lot of crime is drug related;
treatment of addicts works to reduce criminal
behaviour; and drug-using criminals can be
persuaded to enter treatment. Therefore, getting
drug users into treatment will reduce crime. The
case for expanding heroin treatment is now
argued by government as one of the means for
reducing drug-related acquisitive crime.
The drugs–crime focus has mellowed
somewhat in the Labour government’s second
term – but still underpins the Updated Drug
Strategy (Home Office, 2002). Drug treatment
provision is set to double between 2001 and
2008. Much of this new provision will be for
methadone substitution treatment.
However, the Updated Drug Strategy (Home
Office, 2002) also sets out the aim to improve
access to prescribed heroin. The strategy
proposes that ‘all those with a clinical need for
heroin prescribing will have access to it under
medical provision safeguarding against the risk
of seepage into the wider community’. It
acknowledges the currect inconsistency in
providing this treatment and pledges to spend
money on it. Subsequently in May 2003, the
National Treatment Agency for Substance
Misuse (NTA) issued guidance on prescribing
injectable heroin (National Treatment Agency,
2003).
9Heroin is one of a number of drugs – called
opiates – derived from opium. It was first
synthesised at St Mary’s hospital in London in
1874 and, in 1898, it was produced as a new
drug by the German pharmaceutical company
Bayer. Heroin was initially introduced into the
medical world as a respiratory stimulant
(particularly for tuberculosis), though later it
was found to be a respiratory depressant. It was
also widely used as an analgesic. Subsequently,
it was suggested that it might be an effective
cure for morphine addiction but it was soon
found itself to have addictive properties.
Heroin is a strong analgesic and is highly
effective in the treatment of pain. It is mainly
injected. In the UK, it is used to relieve the
severe acute pain caused by injury, surgery, or
heart attack and is used in palliative care for
severe chronic pain experienced by patients
with terminal illness such as cancer.
Heroin also has strong euphoric effects,
produces an intensive feeling of well-being and
can lead to a trance-like sedation – in addict
parlance, ‘nodding off’. The euphoric effect is
more marked when the drug is injected or
smoked than when it is swallowed. Side-effects
can include nausea, dry mouth, reduced
frequency of breathing, reduced appetite and
slowed function of the colon leading to
constipation. In women, regular consumption
can lead to menstrual disorders.
Illicit manufacture
Heroin is derived from the opium poppy. The
largest centres for opium cultivation are in
Afghanistan and Myanmar (formerly Burma),
which together account for over 90 per cent of
global production of illicit heroin. However,
cultivation also takes place elsewhere, for
example, Pakistan, India, Lao PDR, Thailand,
Colombia and Mexico. Many other countries
around the world have suitable climatic
conditions for cultivating opium.
There are various grades of illicit heroin. The
main distinction is between smokeable and
injectable grades. The pinkish brownish ‘base’
heroin volatises when heated and is most suited to
being ‘smoked’. The whitish water-soluble powder
– heroin hydrochloride – is most suited to injection.
The refining of illicit heroin takes place in
clandestine ‘laboratories’. It entails converting
opium to morphine using lime and ammonia,
then converting this into heroin using acetic
acid. Water and chloroform are then used to
reduce impurities. Heroin in this form is
smokeable. A further step in the laboratory
involves conversion of heroin to a water-soluble
powder using ether and hydrochloric acid to
produce an injectable grade of heroin.
It is fairly easy for heroin users to convert
brown heroin into an injectable form using an
acid (e.g. citric acid).
2 Heroin: a brief background
This chapter describes:
• what heroin is
• how and where it is manufactured
• how it is used
• how many people use it
• the harms associated with its use.
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On average, the illicit heroin that is available
in the UK is about 40–45 per cent pure heroin
and this has been so for some years (Home
Office, 2001a). The myth that dangerous
contaminants are often present is largely untrue
(Coomber, 1997). However, other substances are
often added to increase the effect or alter the
taste and give it a distinctive flavour. These are
usually added at the time of manufacture and
include procaine, barbiturates and caffeine.
During the distribution process, relatively
neutral bulking substances such as mannitol,
lactose and powdered sugar are sometimes
added (Carnwath and Smith, 2002).
Using illicit heroin
‘Smoking’ heroin – ‘inhalation’ is the more
accurate term – entails vaporising the heroin
without burning it and then inhaling the fumes.
One method is to ‘chase the dragon’, in which
the heroin is placed on some aluminium foil and
then heated from below using a flame to make it
vaporise rather than burn. The resultant fumes
are inhaled through a tube. The melting heroin
looks a bit like the wriggling of a dragon’s tail
as the heroin user chases the vapour round the
foil. ‘Chasing the dragon’ originated in Hong
Kong and spread to other countries in South
East Asia in the 1960s and 1970s. It is the
predominant mode of administration in the
Netherlands (where it is also called Chinezing).
Heroin base is effectively vaporised at
between 200 and 300∫C. Chasing is an effective
means of heroin administration producing rapid
effects, with about 35–45 per cent of the drug
actually delivered into the body (Hendriks et al.,
2001) but it requires some skill. Heating the
heroin to a higher temperature, as when
burning it with tobacco in a cigarette (at 700–
800∫C), decomposes the heroin and results in
much less of the heroin (10 per cent) being
delivered in the smoke.
If heroin is to be injected, the powder has to
be diluted with water. Heating heroin with an
acid helps make it soluble and some impurities
can be removed using a makeshift filter made
from either cotton wool or a cigarette filter.
Heroin hydrochloride, being water soluble, can
also be inhaled and absorbed through other
mucous membranes. In some parts of South
East Asia, it is rubbed into cuts in the skin.
Injectable grade heroin is not very suitable for
smoking – when heated, the amount of heroin
that is delivered is under 20 per cent. Heroin is
not very effective when swallowed and is
converted by the body into morphine.
How many people use illicit heroin?
The proportion of the UK population who have
taken illicit heroin is small. In 2000, the British
Crime Survey (BCS) found that 2 per cent of
men and 1 per cent of women had taken heroin
at some time, and 1 per cent of men had taken it
in the last year (Home Office, 2001a, p. 81).
Most people who have tried heroin probably
do not go on to become regular users (see Table
1), but no studies have been conducted to
confirm this hypothesis. However, some will
become ‘problematic’ or ‘dependent heroin
users’. The total number of problematic heroin
users in the UK is thought to be in the region of
200,000 (quoted in Home Affairs Committee,
2002a, p. 37) but such estimates are
acknowledged to be imprecise.
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Various indicators suggest that the number
of heroin users has increased. For example:
• the number of heroin addicts in the UK
notified to the Home Office between 1990
and 1996 increased from 14,497 to 30,573
(Home Office, 1995, 1996)1
• in England, in 1993, 7,700 clients new to
drug agencies, or returning after a six-
month gap, said heroin was their main
drug of use (in the six months to end of
September 1993), rising to 22,431 (in the
six months to March 2001) (Department
of Health, 2002a).
The overall popularity of smoking and
injecting changes over time, and differs in
locations around the UK. For example, in
Scotland, the percentage of new clients at drug
agencies who were injecting dropped from 60
per cent in 1999/2000 to 53 per cent in 2000/01,
and the proportion reporting smoking
increased.
What individual and social harms are linked
with heroin use?
Heroin use can affect a drug user’s
psychological health, physical health, social
functioning and legal situation. An individual’s
drug use can have a harmful impact on other
individuals, on their family, or on their
community or society.
Not all heroin users suffer problems, or
suffer them to the same degree. The health
consequences of heroin use will depend on:
1 how the drug is used – including the
route of administration (injecting heroin
is riskier than smoking it), whether it is
taken alone or with other drugs (such as
cocaine) or alcohol, the level of purity and
dose level
2 the characteristics of the drug user –
including pre-existing or co-existing
health, social and economic
circumstances. Harms appear to be
greater when heroin and other drug use is




Prolonged use can lead to dependence that is
both psychological and physical. The physical
basis of dependence is the adaptation of cells to
the presence of heroin. When drug consumption
is reduced or ceases, the resulting withdrawal
symptoms are uncomfortable and include flu-
like symptoms such as fever, sleep disorder,
lachrymation, muscular pain and diarrhoea.
Table 1  Many more people have tried heroin in the UK than have problems with it or are dependent on it –
but the exact numbers are not known
Numbers
People who have tried heroin at some time 1–2% of the adult population = 440,000–880,000
People who are currently using heroin Not known
Problematic and dependent heroin users 200,000 estimated
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Dependence is characterised by an
overwhelming desire to take the drug,
difficulties in controlling its use and a
compulsion to take the drug despite harmful
consequences. ‘Tolerance’ to the drug occurs
when repeated or long-term use requires higher
dosage in order to experience the same effects.
Heroin dependence is aptly described as a
‘chronic relapsing condition’, meaning that
many individuals may be able to stop using it
for short periods, but soon start using again.
Mortality
The mortality rate for chronic heroin users is
about 1.5 per cent a year, both from causes
related to the drug itself (e.g. overdose) and
from accidents and violence associated with a
drug-using lifestyle. The number of opiate
overdose deaths in England and Wales has more
than doubled, from less than 400 in 1993 to
nearly 1,000 deaths in 2000.
Overdose
Overdose risk is increased when heroin is used
in combination with other drugs, in particular
Ten markers of dependence: Leeds Dependency Questionnaire
1 Preoccupation: primacy of thoughts about the drug, how, where, when to procure and use
it.
2 Salience: primacy of activities involved in the procurement and use of the drug over other
routine or once important activities.
3 Compulsion to start: the perceived inability to refrain from use of a drug in the face of
conditioned cues.
4 Planning: the way in which the user’s day is organised around procurement and use of the
drug.
5 Compulsion to continue: the perceived need to continue using the drug in order to enhance
or prolong the drug effects.
6 Narrowing of repertoire: taking the same drug at the same intervals in the same way.
7 Maximise effect: use of a drug in a particular way that maximises the desired effect.
8 Primacy of effect: achieving any pharmacological effect takes precedence over the use of the
preferred drug.
9 Constancy of state: maintenance of a drug-induced state (whether of intoxication, avoidance
of withdrawal or avoidance of a drug-free state).
10 Cognitive set: belief in the need to use the drug in order to cope with everyday life.
(Raistrict et al., 1994)
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with alcohol and tranquillisers such as
benzodiazepines, or when tolerance has fallen
(meaning that a person needs less drugs than
hitherto to achieve the desired effects; for
example, after release from prison or
interruptions of use while in treatment).
Overdose in naive subjects may occur with as
little as 20 mg of pharmaceutical heroin.
However, with prolonged use, tolerance
develops so that larger doses can be consumed
without overdose – a few addicts in London in
the 1960s were using 1,500 mg a day or more of
pharmaceutical heroin. Not all overdoses result
in death. However, heroin overdose deaths are
more likely to occur among people who inject
heroin than among those who ‘chase the
dragon’.
Morbidity
Heroin use has been associated with poor
physical health, such as liver, renal, pulmonary
and cardiovascular diseases, constipation,
reduced sexual drive and fertility.
Diseases transmitted through sharing needles
and syringes
Heroin injectors are at risk of contracting and
transmitting blood-borne viruses through the
sharing of needles and other injecting
equipment. Most significant are HIV and
hepatitis B and hepatitis C. The UK has been
fortunate in avoiding a major epidemic of HIV
among injectors, with less than 1 per cent of
injectors HIV positive. This is due to harm-
reduction services, such as syringe exchange,
methadone treatment, outreach and social
marketing of ‘safer injecting’ messages. There
are many cities around the world that have had
uncontrolled epidemics of HIV and where 40
per cent or more injectors became HIV positive,
for example Bangkok and New York (Stimson et
al., 1998). As a result of harm reduction, the UK
also has relatively low levels – by international
standards of hepatitis B (around 20 per cent)
and hepatitis C (around 38 per cent) – but these
levels are still too high (Hope et al., 2001).
Other injecting-related health problems
Injecting heroin and other drugs also brings
with it the risk of developing abscesses and
infections, and of causing vein damage, vein
blockage and collapse, and deep vein
thrombosis. Injecting heroin is implicated in
other physical complications including
pulmonary embolism (a blood clot in the lungs,
which can cause death), septicaemia (a
generalised bacterial infection of the blood) and
endocarditis (an inflammation of the valves and
lining of the heart). Rarely – but with tragic
consequences – contaminated heroin may lead
to severe infection and death. In Glasgow,
Dublin, Manchester and Liverpool, in 2001, an
unusual and often fatal infection among drug
injectors was caused by batches of heroin
contaminated by the bacterium Clostridium novyi
type A.
Co-morbidity
Mental health problems including affective
disorders (depression) and anxiety or
personality disorder are common among
individuals being treated for heroin
dependence. A recent study found that a
majority of drug users attending drug treatment
agencies had at least one psychiatric disorder. It
is often impossible to determine whether the
mental health problem predates the drug
problem or vice versa (Weaver et al., 2001).
Mental health problems often go unrecognised
by drug services staff.
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Table 2 summarises the wide-ranging problems
associated with problem heroin use. It clearly
shows that the most serious physical harms are
associated with injecting.
Poor health inevitably leads to high levels of
contact with Accident and Emergency (A&E)
departments and with general medical services.
The National Treatment Outcome Research
Study (NTORS) – a large-scale study of drug
users receiving treatment at opiate treatment
services in the UK – found that almost half the
patients had received treatment in an A&E
department and a quarter had been admitted to
a general hospital bed (Gossop et al., 1998).
Social problems
Many heroin users experience relationship
difficulties with sexual partners, friends and
family as a result of their drug use. They may
also have difficulties in holding down jobs and
have financial and legal problems. Many may
become involved in criminal activity to help
fund their drug use.
Crime
There has been much discussion about the
causal relationship between crime and drugs,
and the extent to which heroin or other illicit
drug use leads to law breaking or whether those
committing crimes would do so regardless of
drug use. Indeed, some drug users never
commit any serious crime, other than
possession of an illicit substance, while others
commit large numbers of crimes to pay for their
drug use. Given the high price of heroin – for
example, at an average price of £65 per gram in
the UK (Home Office 2001a, Table 2.8), the only
way many drug uses can afford to buy drugs is
to commit crimes.
The drug–crime nexus was investigated in
the UK in a study of 506 people arrested for a
variety of offences. Drug tests found that 29 per
cent were positive for opiates (including heroin)
and 20 per cent were positive for cocaine
(including crack) (Bennett, 2000). Some 145 of
the 506 arrestees had injected heroin in the
previous year. In this study, on average, heroin
Table 2  Health and social problems associated with problem heroin use
Inject Smoke
Health
Overdose Yes Less common than with injection




Mental health problems Yes Yes
Social
Dysfunctional family and social relationships Yes Yes
Income-generating crime Yes Yes
Work and employment Yes Yes
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users had spent over £16,000 a year on drugs, of
which, on average, about £13,000 came from
illegal sources.
The large UK research study NTORS found
high rates of criminal behaviour among their
treatment sample of drug users, with 61 per cent
reporting 70,728 separate crimes during the
three months prior to entering treatment
(Gossop et al., 1998) – an average of about one
crime a day each. Although shoplifting was the
most commonly reported offence, more serious
crimes such as burglary and robbery were
reported by 12 per cent and 5 per cent
respectively.
The relationship between drugs and crime
was also found in a recent survey of the prison
population. Fifty per cent of people in custody
and awaiting trial admitted they were
dependent on a drug (Home Office, 2001a,
Tables 4.3 and 4.4).
There is still little understanding of the
complex relationship between drugs and crime,
whether using drugs leads to crime (and, if so,
whether it is only to acquire money to pay for
the drugs) or whether those committing crimes
would do so whether they were using drugs or
not.
Note
1 The regulation under the Misuse of Drugs
Act requiring doctors to notify their addict
patients to the Home Office was revoked in
May 1997.
16
The UK has a wide range of services aimed
at reducing or ameliorating drug problems. The
government estimated that around £3.5 billion
was spent on the direct and indirect costs of
drug problems in 2001/02, channelled through a
large number of government departments
(Audit Commission, 2002). About £1,900 million
was spent by the Home Office on enforcement
and prisons, about £265 million on the courts,
£200 million on customs, £738 million on
benefits – and £217 million on treatment.
Spending on treatment in the community and in
prison is set to rise to £573 million by 2005
(Home Office, 2002) as the government plans to
double treatment provision.
Who provides drug treatment services?
The current pattern of treatment provision is
complex and patchy, reflecting uneven growth
and different philosophies of care.
• Community drug teams (CDTs) are NHS
community-based services which
generally aim to provide easy access to
information, advice and counselling, and
general health care. Community
detoxification (see below) and substitute
prescribing are provided by medical staff
or through shared-care schemes with
general practitioners. Some CDTs offer
structured day programmes.
• Street-based agencies are usually run by the
independent sector. They generally aim to
provide easy access to information,
advice and counselling, and outreach (a
community-based activity which attempts
to contact drug users out of contact with
existing services).
• Drug dependency units (DDUs) are usually
situated within NHS hospitals. They
provide assessment and medical
treatment on an out-patient basis. They
characteristically offer treatment to
opiate-dependent drug users and are
staffed by multidisciplinary teams
(nurses, doctors, psychologists and social
workers) led by a consultant addiction
psychiatrist. They provide out-patient
community detoxification, substitute
3 Current approaches to heroin problems
in the UK
This chapter:
• outlines the current treatments for heroin dependence
• shows the limitations of current treatments
• explains maintenance and substitution treatment with methadone and heroin
• describes current regulations for prescribing heroin and how it is prescibed
• shows who prescribes it and how many people get it on prescription
• asks why prescribing heroin is so uncommon in the UK.
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prescribing, counselling, group work and
structured day programmes. Many DDUs
have access to hospital in-patient facilities
for detoxification.
• General practitioners (GPs) are a common
point of first contact for people with drug
problems. The Department of Health has
recommended that GPs provide general
health services to drug users, assessment
and referral, and where possible – and
with the support of specialist services –
detoxification and substitute prescribing.
• In-patient detoxification units are in-patient
units in NHS hospitals or private clinics.
They are either specially designated units
for drug detoxification or have allocated
beds within an in-patient psychiatric
ward.
• Residential rehabilitation units are usually
provided by the independent sector.
Individuals are required to be drug free
and have usually undergone
detoxification before entry. They may be
at the ‘rehab’ for between 12 weeks and
six months, during which time they are
encouraged to explore the reasons for
their drug use and ways to stay abstinent
through counselling and other non-
medical therapies. Residential facilities
are based on different philosophies (e.g.
the 12-step structured programmes,
Christianity-based programmes and
therapeutic communities using a
behavioural model). Residents are
expected and encouraged to support each
other in order to facilitate behaviour
change and remain drug free.
• Crisis intervention units are usually
provided by the independent sector. They
are short-term residential units and
provide counselling, intensive structured
day programmes and sometimes
substitute prescribing to very traumatised
or vulnerable drug users needing
immediate help. Wherever possible, they
refer clients to agencies that can offer
longer-term assistance.
• Self-help groups provide support and
encouragement to individuals with drug
problems. Narcotics Anonymous (NA)
follows the 12-step abstinence-based
approach initially developed by
Alcoholics Anonymous (AA).
How many drug users are in treatment
now?
The precise number of people in treatment for
their drug problems in the UK is not known.
The Department of Health recently reported
that 118,500 drug users were in treatment with
drug services and GPs in England in 2000/01 –
based on a survey of all drugs agencies
(Department of Health, 2002b).
The following are estimates based on a
number of different sources of new treatment
‘episodes’:
• During the six-month period ending 31
March 2001, in England, there were 33,200
new treatment ‘episodes’. Heroin was the
most frequently reported main drug in
22,431 of these, accounting for two-thirds
of users (67 per cent). Fifty-five per cent
of heroin users were injecting.
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• During the same six-month period, there
were, in Scotland, 3,035 new ‘episodes’
involving heroin and, in Wales, 958. In
Scotland, 52 per cent of those where
injecting status was known were injecting
heroin. In Wales, it was 45 per cent.
• There is no information from Northern
Ireland.
What are the main treatments for heroin
users?
There are a number of treatment options
available to people with drug problems. These
include different modalities and encompass
different treatment goals (e.g. counselling,
maintenance, abstinence, etc.). Furthermore,
treatments are delivered in a variety of settings
(e.g. NHS drug dependency clinic; private
clinic; general practice, residential rehabilitation
centre). Many treatments are a mixture of
interventions and approaches – for example,
methadone maintenance is usually
accompanied by counselling. Besides, goals for
a patient may change over time – for example,
treatment may commence with stabilisation on
methadone but with a long-term aim of
abstinence.
• Detoxification is the process by which an
individual dependent on a drug is given
gradually reducing doses of the drug (or
a substitute drug) to eliminate physical
dependence with minimal physical
discomfort from withdrawal symptoms.
This may be achieved by reducing the
dose over days or weeks, either as an in-
patient or as an out-patient in the
community. There are also forms of rapid
detoxification available where
withdrawal may be achieved extremely
rapidly – over 24 hours or so. Clinical
experience and research evidence show
that detoxification alone is normally
insufficient to cope with the range of
problems experienced by people
dependent on heroin. While immediate
withdrawal is relatively easy to achieve,
many people rapidly relapse back to
heroin use.
• Counselling aims to help and support
individuals to bring about personal
change, control their drug use, or prevent
relapse once abstinence has been
achieved. A number of different
counselling techniques are used in the
treatment of drug problems. These
include ‘person-centred counselling’
(derived from Carl Roger’s approach),
cognitive behavioural counselling (often
used in relapse prevention) and
motivational interviewing (helping
individuals to recognise and do
something about their drug problem).
Help in relapse prevention is usually
provided either when an individual is
taking methadone to prevent relapse into
illicit drug use or after an individual has
completed detoxification to help them
avoid taking drugs again.
• Alternative or complementary therapies
include auricular acupuncture,
homeopathic teas and shiatsu massage.
Most remain unevaluated.
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• Structured day programmes aim to
rehabilitate drug users by promoting life
skills and vocational training, building
personal independence and responsibility,
and helping drug users maintain links
with family and friends.
• Twelve-step programmes are based on the 12
steps used by Alcoholics Anonymous.
Problem drug use is viewed as a disease
which the individual has no power to
overcome. Recovery is thought possible
only if the drug user remains completely
abstinent from all drugs and adheres to
the recovery programme. The goal of
treatment is continued abstinence. Twelve
incremental improvements or steps are
made for changing problem behaviours.
• Substitution treatment is a form of medical
care for heroin addicts, where a similar
but safer pharmaceutical drug is
prescribed to replace the one that is being
used illicitly. The idea is to improve
health and social functioning. We deal
with this in more detail in the next
section.
Substitution treatments: methadone and
heroin
Because heroin dependence is a chronically
relapsing condition, and affects multiple
dimensions such as physical dependence and
psychological and social well-being, abstinence
is difficult and often unachievable for many
drug users, at least in the short to medium term.
Prescribing methadone or other alternative
drugs such as pharmaceutical heroin is a form
of substitution treatment where methadone or
pharmaceutical heroin is substituted for illicit
heroin.
Substitution treatment aims to attract drug
users into treatment by offering a prescription
for an opiate substitute, helping them reduce
their risk behaviours, treating and stabilising
health and social difficulties, and then focusing
on treating their physical and psychological
dependence on drugs.
Methadone
Methadone is a synthetic opioid – with a similar
action to the opiates that are derived from
heroin. It is considered by many to be the best
substitute drug for opiate-dependent drug users
because it is easy to administer (usually
prescribed for oral use), it is long acting which
means that it needs to be taken only once a day,
and it is both safe and effective. Treatments
using other opioid drugs (synthetic opiate type
drugs) such as buprenorphine and LAAM (levo-
alpha-acetylmethadol) are also used, but to a
lesser extent.
Substitution treatment with methadone
delays or eliminates heroin withdrawal
symptoms, reduces the frequency of drug
consumption and changes the route of
administration away from injecting (see Table
3). By providing a safe and regular opiate
substitute, it aims to eliminate or at least reduce
risk behaviours (injecting illicit drugs) and thus
the risks of drug-related harms, including
transmission of blood-borne viruses (HIV, HBV
and HCV) and overdose. By reducing the need
for illicit drugs, this treatment aims to diminish
activities involved in obtaining and
administering illicit drugs including criminal
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activities, involvement in the drug scene,
injecting and sharing of injecting equipment. In
the UK, methadone is usually prescribed for
oral use. However, it should be noted that
methadone is also available in injectable form
(in small glass ampoules) and that 10 per cent of
methadone prescriptions in the UK are for
injectable methadone – in such cases, injecting
will continue (Strang et al., 1996) but patients
should experience the other benefits from
receiving methadone treatment.
The evidence suggests that oral methadone
substitution treatment can help reduce the
consumption of illicit drugs, improve the health
of drug users, help them avoid risks of overdose
and infection such as HIV and hepatitis C,
improve social skills and functioning, and
reduce criminality (Farrell et al., 1994; Gossop et
al., 2001; Hall, 1998; Ward et al., 1998).
Methadone maintenance attracts more opiate
injectors than any other form of drug treatment
commonly provided, presumably because drug-
free approaches offer drug users fewer choices
about their drug use and the changes they
would like to make. Also, it is less resource
intensive and therefore less expensive than
many drug-free alternative treatments.
Methadone treatment is generally more
Table 3  Heroin and methadone compared
Heroin injected Oral methadone
Maximum effect Within minutes After 4–5 hours
Duration of effect 6 hours 12–55 hours
Administration 3–4 times a day Once a day
A brief history of methadone substitution treatment
Methadone substitution treatment was pioneered in the USA in the 1960s. Methadone
maintenance was originally designed to be a long-term treatment for opiate dependence in
order to reduce illicit drug use and criminal activity. Later, it was seen to be important for HIV
prevention by helping people reduce or stop injecting. In the USA, lack of public funding at a
local and state level has resulted in limited comprehensiveness of methadone maintenance
treatment. It is estimated that approximately 110,000 people receive substitution treatment in
the USA.
Substitution treatment first appeared in some European countries in the late 1960s, but became
more important from the late 1980s as a response to the HIV epidemic and became widely
available in some EU countries only in the 1990s. All EU countries provide substitution
treatment. Methadone is still the drug most commonly used, accounting for 90 per cent of
substitution treatment in the EU. It is estimated that about 300,000 people receive substitution
treatment in EU countries and 500,000 worldwide.
(European Monitoring Centre for Drugs and Drug Addiction, 2000)
21
Current approaches to heroin problems in the UK
successful than other approaches in retaining
clients – drop-out rates are lower in methadone
treatment than in drug-free programmes. The
two most recent observational studies – the
Drug Abuse Treatment Outcome Study
(DATOS) in the USA and the National
Treatment Outcome Research Study (NTORS) in
the UK – have found significant reductions in
illicit drug use and criminal activity in
methadone maintenance patients (Fletcher and
Battjes, 1999; Gossop et al., 2001).
However, despite encouraging results, there
are some cautionary points to be made about
methadone treatments. Significantly, there are in
fact substantial variations in effectiveness
between programmes in retaining drug users in
treatment, and in reducing illicit drug use and
criminal activity. The quality of the treatment
programme – including the quality of the
clinical staff who work in the treatment agency
– are important in determining the success of
methadone maintenance (Hall, 1998). Overall,
methadone maintenance programmes lose
about a third of their patients in the first 12
months and another third in the following 24
months. The benefits of methadone
maintenance continue only as long as the drug
user stays in treatment – hence, retention is
important (Hall, 1998). While methadone
maintenance can be effective in reducing risk
behaviour, it does not completely eliminate
illicit drug use or crime. Many of those who are
retained in treatment continue to use illicit
drugs albeit in smaller quantities and continue
to commit crimes (but less frequently) (Hall,
1998).
There is no central record of the number of
problem heroin users in methadone treatment in
the UK. A recent estimate suggests that there are
probably in excess of 40,000 drug users in
methadone treatment (see Table 4) – about 20
per cent of the estimated 200,000 problem
heroin users (Matt Hickman, personal
communication, 2003). More heroin users could
probably be drawn into methadone with an
expansion of the service (the government plans
to double the number of treatment ‘slots’). But
not all heroin users want methadone treatment.
Some continue to want their drug of choice,
usually heroin, rather than methadone. Others
may have tried methadone treatment, disliked
it, or found it ineffective. Some patients are
unable to manage on the prescribed dose and
use illicit heroin to ‘top up’ their prescription, or
may dislike the clinic rules and regulations.
Some injectors are unable or unwilling to give
up injecting. The ritual of injecting is an
experience that sometimes becomes a focus for
addiction (Carnwath and Smith, 2002). Some
heroin users do not want any treatment at all –
they may decide that they do not have a
problem, that they do not want to stop using
Table 4  Only a small proportion of heroin users in the UK are in treatment with methadone
Numbers
People who have tried heroin at some time 1–2% of the adult population = 440,000–880,000
People who are currently using heroin Not known
Problematic and dependent heroin users 200,000 estimated




heroin, or that they do not like treatment
services.
Prescribing heroin
There is no central record of the numbers of
doctors prescribing heroin or of the numbers of
drug users receiving a prescription for heroin.
Previous research studies have provided only
an indication of the extent of heroin prescribing.
Therefore, in 2000, the Centre for Research on
Drugs and Health Behaviour conducted postal
surveys of:
1 all doctors holding a licence from the
Home Office to prescribe heroin, in order
to determine the scale and practice of
heroin prescribing in the UK
2 all consultant psychiatrists or clinical
directors of drug clinics not holding a
licence to prescribe heroin, in order to
determine their reasons for not requiring
such a licence.
This study will be referred to as ‘our survey’
(Metrebian et al., 2002).
Our survey found that, in the year 2000,
there were 70 doctors holding a Home Office
licence to prescribe heroin. Not all were using
their right to prescribe and only 46 were
currently prescribing heroin. The majority of
doctors who prescribed (28) were consultant
addiction psychiatrists, nine were consultant
general psychiatrists with an interest in
addiction, six were junior doctors and two were
general practitioners.
For most of these doctors, methadone was
the main drug prescribed and they had only a
small number of patients to whom they
prescribed heroin. Most of the doctors
prescribed heroin to between one and nine
patients, 14 doctors prescribed to between ten
and 50 patients, five of the 14 doctors were
prescribing heroin to between 30 and 50
patients.
There was very uneven geographic
distribution of heroin prescribers, with the
majority living in London (nine), the South East
(nine) and the North West (seven), three in
Wales and none in Northern Ireland and
Scotland. Consequently, there were regional
variations in the number of drug users receiving
a prescription for heroin. The majority of
patients were in the North West of England.
The history of the service, the personal
preferences of the prescribing doctors and
individual NHS trusts’ policies on prescribing
heroin determine the current level of heroin
prescribing. In our survey of doctors who
prescribed heroin, nearly half (21/46) had not
themselves initiated the prescription for heroin,
but had ‘inherited’ these patients from a
previous physician and continued to prescribe
heroin. Many were reluctant to prescribe. About
40 per cent (18/46) of doctors said that they
prescribed heroin because it provided an
opportunity for clinical improvement. Three
prescribed heroin to help attract and retain in
treatment hard-to-reach drug users.
How many heroin users receive
prescriptions for heroin?
Heroin does not figure prominently in the
treatment of opiate dependence. Our survey
identified that there were about 448 patients on
heroin, compared with about 40,000–80,000 on
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methadone. In 1995, prescriptions for heroin
accounted for under 2 per cent of all
prescriptions given for the treatment of opiate
dependence compared with prescriptions for
methadone which comprised 96 per cent of the
total (Strang and Sheridan, 1997). Despite an
increase in the volume of methadone
prescribing in recent years, the numbers
receiving heroin are small and relatively stable,
probably not exceeding about 448 since 1975.
This is a decline from the late 1960s when there
were probably about 1,000 patients on
prescribed heroin.
The numbers of patients receiving heroin is
not necessarily dependent on the number of
doctors prescribing it (see Table 5). In the North
West, seven doctors were prescribing to 128
patients compared with nine doctors
prescribing to 42 patients in the South East.
Table 5  Doctors prescribing heroin and patients receiving heroin in 2000, and number of new treatment
episodes with heroin as the main drug
Patients Number of
receiving heroin  new treatment
Doctors (a) episodes Comparative
prescribing % of  involving heroin index of ‘need’
heroin N total (b) (a) as % of (b)
England 43 419 26,424 1.7
Northern and Yorkshire 5 27 6 5,021 0.5
Trent 6 46 10 3,261 1.4
Eastern 1 5 1 1,381 0.4
London 9 93 21 3,408 2.7
South East 9 42 9 1,767 2.4
South West 4 56 13 2,530 2.4
West Midlands 2 22 5 2,035 1.1
North West 7 128 33 3,028 4.9
Scotland – – 3,035 0.0
Wales 3 29 2 958 0.9
Northern Ireland – –
Neither does the distribution of patients
approximate to need. A rough comparative
measure of need is the number of new treatment
episodes where the patient said that heroin was
their main drug. Assuming that roughly the
same proportion of patients would be eligible
for heroin in each region, our crude measure is
the ratio of patients getting heroin to the total
number of new heroin patients. This varied
from 0 per cent in Scotland to 4.9 per cent in the
North West.
We do not know how many people are
started on a prescription for heroin for the first
time each year, but many patients have been
receiving prescriptions for heroin for a long
time. It is reasonable to assume that very few
heroin users are started on a heroin prescription
for the first time each year.
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Current regulations for heroin prescribing
Heroin is controlled under the Misuse of Drugs
Act 1970, which covers offences of possession,
possession with intent to supply and supply.
Heroin can be prescribed by any medical
practitioner in the treatment of medical
conditions but, in order to prescribe it in the
treatment of addiction, a doctor needs a licence
from the Home Office. Licences are generally
given only to consultant addiction psychiatrists
working from NHS drug dependency units.
Licences are valid only for a specific address
and are renewed every three years. Applications
for licences require a recommendation from the
doctor’s health authority and from a senior
medical officer in the Department of Health.
There are requirements about how prescriptions
are written.
Pharmacists dispensing prescriptions for
heroin must record details of the prescription in
their controlled drugs register. These registers
are open to inspection by the Home Office
inspectors and police.
Many people – especially from countries
with a tradition of tight control of opiates – are
surprised that the UK has relatively few
restrictions and regulations for heroin
prescribing to addicts. For example:
• There are usually no restrictions on the
amount of heroin that licensed doctors
may prescribe, nor on how many patients
they may prescribe heroin for. However,
the Home Office can impose any
restrictions they wish on a doctor (for
example, a doctor may be restricted to
prescribe heroin for one named patient
only, for a limited number of patients, or a
doctor – usually a clinical assistant – may
be restricted from initiating prescriptions).
• There is no requirement for doctors to get
permission to prescribe for particular
individuals or to report details of patients
for whom they prescribe.
Until 1997, all doctors were required to
‘notify’ their addict patients to the Chief
Medical Officer at the Home Office (i.e. provide
information about their addiction treatment).
However, this requirement has since ceased.
One consequence is that there is now no central
database recording the number of drug patients,
their characteristics or the treatment they are
receiving.
There has also, until recently, been very little
in the way of guidance for doctors. For most of
the period under discussion there were no
national treatment guidelines on prescribing
heroin, and no agreed treatment protocols. In
1999, the Department of Health issued
guidelines on the clinical management of drug
dependence, but the section on prescribing
heroin is extremely brief.
Prescribing heroin: a system without a
plan
The current provision of heroin is not part
of any plan on the part of local health
services, rather something that has
developed in a rather haphazard way. This
lack of a plan means that there are large
parts of the UK where the option of a
heroin prescription is not available. The
arbitrary way in which treatment with
heroin has developed is typical of drug
service development – as noted by the
Audit Commission (2002, p. 34).
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These guidelines are not legally enforceable
but their breach can be taken into account in
professional disciplinary cases brought before
the General Medical Council.
There are few safeguards to ensure that
drugs are used by the individual for whom they
are prescribed and not sold or diverted onto the
illicit market. Some prescribers may ask patients
to return their used ampoules before receiving
another prescription, but this is not done
routinely.
The Home Office Drugs Branch monitors
aberrant heroin prescribing through information
received from pharmacists, the police and
others, and this sometimes identifies doctors
who are self-medicating with heroin. Indications
are that there is not a major illicit market in
pharmaceutical heroin.
Consequent to the new interest in prescribing
heroin expressed by the government, the
National Treatment Agency for Substance Misuse
issued guidance on prescribing injectable heroin
in May 2003. This guidance was not effective
during the period described in this chapter. The
new guidance will be discussed in Chapter 5.
Current prescribing practice
Heroin is usually prescribed by a doctor
working in a drug dependency clinic and
dispensed from a community or hospital
pharmacy for unsupervised injection at home.
On entering treatment, the initial dose of
heroin may be supervised to check tolerance
and injecting practices. However, regular and
ongoing supervision of injecting is rare.
Injecting equipment such as needles, syringes,
antiseptic swabs for cleaning the skin and
disposal bins for used injecting equipment are
either supplied by the clinic or obtained from
community pharmacies or a syringe exchange.
Patients can bring their full disposal bins back
to the drug clinic or to a syringe exchange.
Sterile water for injecting purposes requires a
prescription and is dispensed with the drugs.
Most doctors prescribe heroin as a freeze-
dried powder contained in ampoules for
injection (about 75 per cent of prescriptions).
These must be mixed with sterile water in order
to be injected. Some doctors prescribe heroin in
other forms, e.g. in tablet form to be taken
orally, as a powder to be mixed with water for
Department of Health 1999 guidelines on prescribing heroin
Diamorphine (heroin):
A short-acting opiate agonist, mainly used intravenously, but can also be taken in oral form and
inhaled. It is used as part of a maintenance regime in a minority of patients. A Home Office
licence is required for such prescribing, which is the preserve of specialists. Diamorphine should
only be prescribed in situations of rigorous monitoring and where use in the initial stages can be
supervised. With the availability of injectable methadone, there is very little clinical indication for
prescribed diamorphine. All the caveats and criteria discussed with regard to injectable
methadone apply to diamorphine.
(Department of Health, 1999, p. 57)
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injection (or occasionally for smoking), as a
solution to be taken orally, or as heroin-
impregnated cigarettes (reefers) to be smoked
(Metrebian et al., 2002).
Daily doses of heroin range between 5 and
1,500 mg, with the minimum average (median)
daily dose of 90 mg and the maximum daily
dose averaging 460 mg (Metrebian et al., 2002).
In a survey of pharmacists, the mean dose of
prescribed heroin was 175 mg (median 130 mg)
(Strang and Sheridan, 1997).
There is a lack of consensus about the
equivalent doses of methadone and heroin.
Knowing how a dose of heroin equates with a
dose of methadone helps the doctor prescribe
the correct dose of heroin to a patient who
wishes to transfer from a methadone
prescription to heroin. In our survey, we asked
doctors to estimate the equivalence dose of
heroin for 100 mg injectable methadone. The
doctors’ estimates varied widely: from 50 mg of
heroin to 900 mg of heroin (Metrebian et al.,
2002). However, the Department of Health
clinical guidelines (Department of Health, 1999)
report that 60 mg of methadone is equivalent to
a 30 mg ampoule of pharmaceutical heroin.
Heroin – like other controlled drugs – can be
dispensed in instalments by community
pharmacists, following the prescribing doctor’s
instruction (under the Misuse of Drugs
Regulations 1973). Heroin is usually dispensed
daily (though generally not on Sunday) or a few
times a week. Heroin prescriptions are more
likely than methadone to be dispensed on a
daily basis (74 per cent) compared with
methadone (38 per cent) (Strang and Sheridan,
1997).
There is little consensus among doctors
about who is eligible to enter heroin treatment.
Most agree that it is a treatment for entrenched
heroin injectors who have not been helped by
other treatments. In our survey of prescribing
doctors, half reported that, to be prescribed
heroin, patients needed to have failed previous
treatments with oral methadone – either
detoxification or maintenance, and some
doctors mentioned that the patient should also
have previously tried injectable methadone.
Many indicated that patients should have a long
history of opiate dependence and injecting – but
long meant anything from between two and ten
years (Metrebian et al., 2002).
Beyond these indicators, there were few
other factors that were consistently mentioned.
Some doctors said that patients must be
generally compliant, not dependent on other
drugs, be able to inject safely in either arms or
legs with no injecting in the groin or neck, have
no history of severe mental disorder or active
psychosis, be socially stable, or have physical
complications such as HBV, HCV or HIV. There
were others, however, who took a different view
and said it was the unstable patients who were
most likely to benefit from heroin treatment.
Why is there so little prescribing of heroin
for the treatment of opiate dependence in
the UK?
It is striking that, while the UK has few
restrictions on prescribing heroin for the
treatment of opiate dependence, few doctors
actually prescribe it, and only to a few patients.
Among those doctors who prescribe heroin are
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some who think heroin has an important
treatment utility and others who do so
reluctantly and only because they have
inherited patients from others.
Our survey of licensed doctors (Metrebian et
al., 2002) and of doctors eligible for licences but
who had not sought a licence found that the main
reasons given for not prescribing heroin were:
• not good clinical practice – due to the
possibility of diversion of the drug to the
black market; that it encourages
dependency; that it encourages injecting
and increases the risk of infection,
overdose and respiratory problems
• lack of need because most patients could be
made comfortable with oral methadone
• lack of demand – few drug clinic patients
ask for a heroin prescription
Resources for prescribing heroin
Many respondents cited lack of appropriate resources as a reason for not prescribing diamorphine
to more patients. This included inadequate funding and the unavailability of facilities for
supervised injection. To prescribe for more than a handful of patients is therefore beyond the
budget of most drug teams, whatever the arguments about cost-effectiveness might be in terms of
health and forensic gains. Supervised injection would require attendance at special injecting
rooms two or three times a day, and would therefore increase the cost of the treatment.
(Metrebian et al., 2002, p. 1160)
• potential for high demand – which may be
generated if heroin becomes easily
available: ‘honey-pot effect’
• lack of evidence for effectiveness, or for its
superiority over oral methadone
• disadvantages compared with methadone –
short half life; that only injectable forms
are readily available
• lack of guidelines to best practice
• lack of financial resources – its high cost
compared with methadone; financial
pressure to keep costs to a minimum; no
budget for prescribing diamorphine
• lack of facilities – e.g. for supervised
injecting.
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The evidence base for the effectiveness of heroin
as a treatment is rather limited – four small-
scale studies in the UK, one large study with
multiple components in Switzerland
(hereinafter referred to as the Swiss trial) and
two large trials in the Netherlands. One reason
for such a dearth of research is that heroin is
prohibited for use in the treatment of opiate
dependence in many countries, and pressure
has been brought to bear from the International
Narcotics Control Board against countries
wanting to conduct research trials on this topic.
Another is the cost of trials. The Canadian trial
is expected to cost $CAN 8.1 million.
There have been four randomised controlled
trials – one in the UK (Hartnoll et al., 1980, one
in Switzerland (Perneger et al., 1998) and two
large trials to assess the efficacy of both
injectable and smokeable heroin treatment in
Holland (van den Brink et al., 2002).
4 Effectiveness of prescribing heroin
Questions about prescribing heroin are easier to ask than to answer. The key issues are:
• Is prescribing heroin feasible? How is the treatment delivered and are there any problems with
delivering it?
• Do heroin users want heroin? Does prescribing heroin attract and retain heroin users in treatment?
• Is prescribing heroin effective? Does the treatment work and is it better than the other treatments?
• Who benefits most from the treatment? Who should receive it?
• Is it cost-effective? Do the benefits of the treatment outweigh the additional cost of the treatment
when compared to other treatments?
UK studies of heroin prescribing
Stimson and Ogborne (1970); Stimson and Oppenheimer (1982). A follow-up study, started in
1969, of a randomly selected sample of one in three heroin users attending the first London
drug clinics and being prescribed heroin. Patients were followed up at seven (Thorley et al.,
1977), ten (Wille, 1981) and 22 years (Tobutt et al., 1996).
Hartnoll et al. (1980). Ninety-six opiate-dependent injecting drug users randomly allocated to
receive either injectable heroin maintenance or oral methadone maintenance and followed up at
12 months.
McCusker and Davies (1996). Twenty-seven drug users receiving a prescription for heroin
(injectable and smokeable) at one drug clinic compared with 39 receiving oral methadone at
two other clinics in one regional health authority.
Continued
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Problems of conducting research on heroin
Before looking at what can be concluded from
the evidence, we highlight some of the problems
in conducting research and interpreting the
evidence.
Complexity
Randomised controlled trials, comparing one
treatment against either no treatment, minimal
treatment or a comparison treatment, are
considered the ‘gold standard’ for measuring
effectiveness, but are difficult to undertake with
problem drug users. Randomly allocating
patients to different treatments ensures that
patients in each treatment are similar, so that
any differences found between the two groups
can be attributed to the differences in treatment
rather than differences in the patients. The
complexity and logistics of such trials can be
seen in the example of the Dutch heroin trial,
summarised in the box overleaf.
Metrebian et al. (1998, 2001). Fifty-eight long-term opiate-dependent drug injectors who had
previously tried and failed oral methadone treatment were offered the choice to receive either
injectable heroin or injectable methadone and followed up for 12 months.
The Swiss heroin trials
Uchtenhagen et al. (1997, 1999). Five linked studies to evaluate heroin prescribing were
undertaken between 1994 and 1996 involving 1,000 subjects. Eight-hundred chronic heroin
addicts who had failed in drug-free or methadone-substitution treatments were prescribed
heroin and provided with psycho-social interventions at a number of treatment centres
throughout Switzerland (as part of these five studies) and followed up at 12 and 18 months.
While this was not a randomised controlled trial, this study is usually referred to as a trial and
will be referred to as such hereinafter.
Perneger et al. (1998). A randomised controlled trial in Geneva of 46 long-term dependent
heroin users who were randomised to either receive a prescription for heroin or were put on a
waiting list where most received oral methadone.
The Dutch heroin trial
van den Brink et al. (2002). Two large multicentre randomised control trials were undertaken
involving 625 patients from eight treatment units located in the Netherlands. The trials were
designed to assess the effectiveness of heroin, co-prescibed with methadone – i.e. all patients
were on methadone and some, in addition were given inhalable or injectable heroin. These
were compared with people who got only methadone.




There are at least two stakeholders who might
or might not benefit from prescribing heroin: the
drug-using patient and the community.
Research has to take into account the varying
and sometimes contradictory aims of
prescribing. The reasons for prescribing heroin
might focus more on health gain, or on reducing
crime – depending on the political context of the
research and who is paying for it. It cannot be
assumed that positive outcomes will be seen in
all areas. Typically, individual outcome
Clinical trials are complex and difficult to set up and run – the Dutch example
• Lead time of three years (1995–98): study design and feasibility, establishing collaborations,
finding treatment sites, drafting treatment protocols, recruiting and training staff, obtaining
heroin and providing for its safe keeping, building rooms where patients can smoke or inject,
getting permissions from government, health and local authorities, pharmaceutical
regulatory bodies and trials ethics committees.
• Collaborations: the Ministry of Health, Welfare, and Sports commissioned the study. The
Central Committee on the Treatment of Heroin Addicts was responsible for the
development, conduct and scientific quality of the study. The National Research Board was
responsible for technical and scientific aspects. The Inspectorate of Health Care examined the
quality of the care. The National Safety Committee advised on the evaluation of severe
adverse events and the National Committee on Public Order and Controllability advised on
public order and public safety. The Central Committee on Medical Ethics vetted the trial
protocol. Each city developed a protocol with respect to public order.
• Eligibility: the trial had ten ‘inclusion criteria’. ‘Treatment refractory’ was defined as
treatment-resistant heroin dependency of at least five years; minimum 60 mg of methadone
per day for an uninterrupted period of at least four weeks in the previous five years; in the
previous year, registered in a methadone programme and, during the previous six months,
in regular contact with the methadone programme; chronic heroin addiction and
unsuccessfully treated in methadone maintenance treatment; daily or nearly daily use of
illicit heroin; and poor physical and/or mental and/or social functioning. There were also 14
‘exclusion criteria’.
• Randomisation: eligible patients were divided into injectors and smokers, and randomly
assigned to receive standard oral methadone treatment (Group A) or to receive heroin
(Groups B and C). Group B were assigned to methadone and heroin for 12 months, while
group C continued on methadone for six months and then switched to heroin.
(van den Brink et al., 2002)
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measures include: health and psychological
well-being, illicit drug use, HIV risk behaviour,
criminal behaviour and social functioning.
Community outcomes might include: levels
and types of crime occurring in the community
linked with heroin use; overall availability of
illicit drugs and diversion of prescribed drugs
onto the illicit market; heroin users migrating to
the area to get treatment; public safety and
sensitivity (e.g. patients loitering around the
clinic, used injecting equipment left in public
places); and effects on other health and social
services in the area (e.g. emergency hospital
admissions, additional burden on law
enforcement and social services).
Cost-effectiveness
Prescribing heroin is more expensive than oral
methadone. It is necessary, therefore, to
demonstrate that heroin prescribing provides
added advantage over standard treatment in
order to justify its use. Thus, a health economic
assessment needs to be conducted to establish
whether prescribing heroin results in greater
economic benefit per extra unit of resource
invested in the treatment, compared with
prescribing oral methadone.
Treatment components
Treatment components provided in addition to
the prescription for heroin may affect outcome.
All research studies have evaluated the
effectiveness of prescribing heroin with
additional psycho-social services. In
Switzerland, the large research study evaluated
the prescription of heroin with additional social
and psychological interventions. Because there
was no comparison treatment group in the main
study, it is impossible to say whether treatment
success was due to the pharmacological effects
of heroin, the social and psychological
interventions, or the fact that treatment was
given in well resourced clinics with motivated
staff offering both pharmacological and
psychological treatment (Farrell and Hall, 1998).
Recruitment and eligibility
Studies recruit different types of patients. In the
Netherlands, heroin was offered to people
already in methadone treatment and offered in
addition to methadone. In Switzerland, heroin
was offered to drug users newly presenting for
treatment. All treatment trials have a high level
of control over the treatment delivered –
essential because of the requirements of
scientific measurement. However, ‘real-life’
treatment is rarely delivered in the same
rigorous way as in a clinical trial – this is true of
all of medicine.
Generalisability
Studies in other countries may provide useful
information, but, since the treatment context
differs, it is unclear how far results from these
studies are generalisable. For example, patient
interest in participating in a trial will be
influenced by the history of treatment in that
country (e.g. in Switzerland, heroin was not
available before; in the UK, it is currently
available). It will also be influenced by the
accessibility, availability and quality of other
treatments. Recruitment of patients and their
response in a heroin trial may well be different
between the Netherlands, where there is good
methadone coverage (methadone is generally
available to those who need it) and Canada,
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where coverage is poor. Other factors will also
be important – for example, in the Netherlands,
there is good provision of housing and welfare
services, while, in Canada, this provision is
poor. Legal penalties might make treatment
more or less attractive to patients.
Comparing the UK, Swiss and Dutch
evidence shows up differences in the way in
which heroin treatment is delivered. The
question ‘does prescribing heroin work?’ has to
consider whether it works when it is delivered
in a particular manner, in a particular treatment
modality, in a particular treatment and country
context.
What does the research indicate about the
effects of heroin prescribing?
1  Implementation and feasibility
Prescribing heroin is practical in specialist
treatment settings
Practical considerations include drug storage
and security, dispensing and supervision of the
consumption of heroin ampoules and powder
for smoking. Studies conducted in the UK have
not involved supervised consumption; however,
they suggest that the storage, control and
dispensing of heroin is practical. Studies in the
Netherlands (van den Brink et al., 2002) and
Switzerland (Uchtenhagen et al., 1999) where
the prescription was supervised have found the
prescribing of heroin to be practical in specially
established drug treatment clinics.
Heroin is as safe for patients as other
comparable treatments where injectable drugs
are prescribed
No serious side-effects were reported in
toxicology studies in Switzerland (Brenneisen,
1997; Uchtenhagen et al., 1999). Fewer mild side-
effects were reported by patients receiving
injectable or oral heroin compared to those
receiving methadone or morphine
(Uchtenhagen et al., 1999). The Dutch trial found
that the incidence of serious side-effects was
comparable to patients receiving oral
methadone (van den Brink et al., 2002).
Prescribing is safe for clinic staff
Incidents of negative behaviour by patients
directed at clinic staff (e.g. disputes, aggression,
violence) are no different from other treatments
(Uchtenhagen et al., 1999; van den Brink et al.,
2002).
Prescribing heroin does not pose problems for
the community
Neither the Dutch nor the Swiss trials
experienced any serious public order or safety
problems in the surrounding neighbourhood
(Uchtenhagen et al., 1999; van den Brink et al.,
2002). Studies in the UK found little or no public
order problems. A few patients were found to be
injecting their drugs in the local vicinity and
were then given the opportunity to inject at the
clinic (Metrebian et al., 2001).
Prescribed heroin is not diverted to the black
market
In the UK, heroin is prescribed for take-home
consumption. To date, there is little evidence
that prescribed heroin is diverted onto the illicit
market. However, with unsupervised
consumption, diversion might become a
problem if the provision of prescribed heroin is
substantially increased. In Switzerland and in
the Netherlands, consumption is supervised
and diversion is not a major issue.
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Patients can be maintained on a stable dose of
heroin
It appears that most patients can be maintained
on a stable non-increasing dose. The Swiss trial
showed that, after the first few months, doses
were more likely to decrease than increase and
that patients were stabilised on between 500 and
600 mg a day (Uchtenhagen et al., 1999). In the
UK (Metrebian et al., 1998) and in the Dutch and
Swiss trials, additional oral methadone was
generally prescribed to stop night-time
withdrawal and reduce the number of times
patients needed to inject heroin. Overall, doses
of heroin prescribed are much lower in the UK
than in Switzerland and the Netherlands (see
Table 6).
2  Attraction and retention of target group
It is uncertain whether heroin prescribing
attracts more drug users into treatment
There has been no research to examine whether
prescribing heroin attracts patients into
treatment. Metrebian et al.’s study (1998) and
the Swiss randomised controlled trial (RCT)
(Perneger et al., 1998) both took some time to
recruit patients to participate in the trials,
suggesting that there was no ‘honey-pot’ effect.
In Switzerland, the regime of supervised
consumption may have discouraged some
patients from applying for the trial.
It does not appear to discourage patients from
accepting oral methadone treatment
Metrebian et al. (1998, 2001) found that, offered
the choice between receiving injectable
methadone or heroin, one-third of patients
chose methadone, indicating that heroin is not
always the drug of choice. The 200 mg per day
upper limit imposed on both methadone and
heroin prescriptions resulted in a potentially
greater dose of methadone being offered than
for heroin (it is usually in the region of 60 mg)
and this may have influenced patient choice.
Many patients who chose methadone reported
that they did not want to inject frequently
(which they felt they would have to do if they
were receiving a prescription for heroin due to
Table 6  Daily doses of heroin
UK Switzerland3 Netherlands4
Regulation or guideline No upper limit None 1000 mg daily and no single
dose greater than 400 mg
In practice Range 5–1,500 mg1 500 mg for Mean 549 mg for
injectable heroin  injectable heroin
Mean 175 mg2 1,000–1,850 mg for Mean 539–47 mg for
smokeable heroin smokeable heroin
Notes:
1 Metrebian et al. (2002)
2 Strang and Sheridan (1997)
3 Uchtenhagen et al. (1999)
4 van den Brink et al. (2002)
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heroin’s shorter half-life). Research from
Switzerland found that, of those discharged
from treatment after one year, 37 per cent left to
receive oral methadone (Rehm et al., 2001).
Patient retention in treatment is equal to or
better than for methadone treatment
UK research indicates that prescribing heroin
helps retain more drug users in treatment than
oral methadone. Hartnoll et al. (1980) in a
randomised controlled trial found at 12 months
that a greater proportion of patients were
retained in heroin treatment than in oral
methadone treatment (74 vs. 26 per cent).
Similarly, McCusker and Davies (1996) found
that only one of 27 patients in a heroin group
left treatment during the six-month follow-up
period compared to 14 of 39 in the methadone
group. However, the groups were receiving
treatment from different drug clinics, thus
differences may have been due to the
differences in the way treatment was delivered,
rather than to the drug prescribed. Metrebian et
al. (1998, 2001) found that those prescribed
heroin were more likely to remain in treatment
at 12-month follow-up than those on injectable
methadone (59 vs. 48 per cent). However, the
number of patients studied was small and,
while both groups received similar treatment,
drug users were able to choose their treatment
rather than being randomly allocated to
treatment. Thus, it is possible that any
differences in outcome between the two
treatment groups may be attributable not
merely to the differences in their treatment
regimes but also to other factors (e.g. differences
in personal characteristics, previous drug
history, etc.). Moreover, the overall retention
rate at 12 months was higher than that reported
by the National Treatment Outcome Research
Study of oral methadone maintenance
programmes at 12 months (59 vs. 38 per cent).
None of the UK studies required supervised
consumption of heroin. Trials that had
supervised consumption provide conflicting
results.
The Swiss heroin trial found that 70 per cent
were retained in treatment at 12 months, but
there was no comparison oral methadone
treatment (Uchtenhagen et al., 1999).
The Dutch heroin trial found that those
prescribed injectable heroin were only
marginally less likely to be retained in treatment
than the methadone group and those who were
prescribed heroin for inhalation were less likely
to remain in treatment than the methadone
group (van den Brink et al., 2002).
3  Effectiveness – at an individual level
Illicit use of heroin and other drugs decreases
but is not eliminated
All studies found that illicit drug use (reported
by urinalysis and self-report) reduces during
treatment and (where available) by comparison
to controls, but was not eliminated in all
patients. Both Hartnoll et al. (1980) and
Metrebian et al. (1998) found that illicit drug use
was reduced but not eliminated. The Swiss trial
showed significant reductions in illicit drug use
among those still in treatment but there was no
control group to assess whether similar findings
would have been found with oral methadone.
However, the RCT (Perneger, 1998) conducted
in Switzerland found that, at six months, none
of the study patients receiving heroin was using
illicit heroin on a daily basis, compared to
nearly half of those on the waiting list (many
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receiving oral methadone). The Dutch trial (van
den Brink, 2002) found similar results; at 12-
month follow-up, only half the study
participants receiving heroin were using illicit
drugs.
Health improves
Hartnoll et al. (1980) found no evidence of
improved health with heroin prescribing,
although HIV was not an issue at the time the
study was conducted. Recent studies have
measured physical health symptoms, mental
health, overdose and risk of infection with
blood-borne viruses (HIV, HBV, HCV). Most
find health improvements but the lack of
controls makes definitive conclusions difficult.
Metrebian et al. (1998) found significant
improvements in health but the lack of control
group makes it impossible to know whether
similar gains would have been made had study
participants been receiving oral methadone. The
Swiss trial found improved health but, again,
had no control group receiving oral methadone
(Uchtenhagen et al., 1999). However, the Swiss
RCT did find health improvements (Perneger et
al., 1998). The Dutch trials found that, at 12
months, health had improved significantly more
in the heroin group than in the methadone
group (van den Brink et al., 2002).
Social functioning improves
Findings from the Swiss trial showed that, at 18
months, patients’ accommodation situation had
improved, there was a nearly twofold increase
in number of patients achieving permanent
employment and a decrease in the numbers of
patients regularly in contact with other drug
users (Uchtenhagen et al., 1999). The Dutch trial
and studies in the UK found similar results.
However, substantial numbers of patients
remained unemployed (Metrebian et al., 1998;
van den Brink et al., 2002).
Patients commit less crime than before being
prescribed heroin
Hartnoll et al. (1980) and Metrebian et al. (1998)
found that crime reduced but was not
eliminated. The Swiss trial (Uchtenhagen et al.,
1999) showed that self-reported criminal activity
progressively reduced and, 12 months after
entering treatment, the majority of patients had
no convictions while in treatment. The Dutch
trial found similar results; at 12-month follow-
up, only half the study participants receiving
heroin were involved in crime (van den Brink et
al., 2002). Again, those in the heroin group had
reduced their criminal behaviour, but criminal
behaviour remained high among the control
group. All studies found crime had reduced
compared to levels at entry to treatment and
where available to controls.
Patients tend not to switch to methadone or
oral routes of administration particularly
when injecting is unsupervised
There is little evidence to suggest that
prescribing heroin will help change drug users’
route of administration from injecting to oral
routes. Hartnoll et al. (1980) found that the
majority of the heroin group continued to
receive a prescription for an injectable drug.
Similarly, Metrebian et al. (1998) found that only
a few patients changed from injecting to oral
methadone use. Other UK research found that
one-third of a sample of drug users prescribed
heroin by the early London drug clinics were
still receiving a prescription for heroin seven
years later (Thorley et al., 1977). These UK
studies suggest that prescribing heroin without
regular supervised injection might reduce the
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motivation to stop injecting. However, research
from Switzerland found that of those
discharged from treatment by one year, 30 per
cent moved on to other treatments.
It is not clear who does best on the treatment
The research evidence comes from patients with
long injecting careers who have previously tried
and not been significantly helped by oral
methadone treatment. It is not known which
problem drug users would most benefit. Most
studies have not been designed in a way that
can answer this question.
4  Effectiveness – at a community level
There is no evidence that the current extent of
heroin prescribing undercuts the illicit market
in drugs or reduces drug scenes
Studies have used only individual measures of
illicit drug use and have shown that prescribing
heroin reduces illicit drug use; there is thus a
potential impact on drug markets and drug
scenes. However, as the number of patients
prescribed heroin remains small, the overall
effects on the drug markets is likely to be
difficult to measure.
5  Costs and cost-effectiveness
Prescribing heroin is more expensive than
methadone
Assuming that other services continue at the
same level, i.e. that a person on heroin needs the
same amount of staff time and other resources
as a patient on methadone, then the main costs
that vary are those of the drug itself and the
extra costs for the supervision of injecting or
smoking the drug. Current information suggests
that the price range for prescribing methadone
per patient, per year ranges from £1,320 to
£3,550 in developed countries (Centre for
Addiction and Mental Health, 2002; Ministry of
Health, 1996; National Evaluation Data Services,
1999; National Institute on Drug Abuse, 1999;
Netten and Curtis, 2001; Substance Abuse and
Mental Health Services Administration, no
date). In the UK, the total costs per patient per
year of £2,800 include capital and revenue costs
of £36 per patient per week and methadone
costs of £18 per patient per week. Figures are
not available separately for oral and injectable
methadone.
In the Swiss trial, the annual patient cost for
a patient receiving heroin was £8,030
(Gutzwiller and Steffen, 2000) and, in the
Netherlands, between £9,775 and £17,109 (van
den Brink et al., 2002). These costs included
labour, medical material, substitute drugs,
laboratory costs, rent, maintenance, energy and
administration, including depreciation. This is
substantially higher than costs for methadone,
but the trials required special facilities (e.g. in
the Netherlands, separate heroin injection and
inhalation rooms, each with specific technical
requirements), which were resource intensive
with daily visits by patients for supervised
consumption.
In the Dutch heroin trial, the main costs were
for nurses (around 30 per cent of costs). Nurses
were required to be present to supervise the
self-administration of heroin by the patients.
Based on a minimum presence of two nurses
during the opening hours of a treatment clinic,
with working hours from 7.30 a.m. to 8.30 p.m.,
and taking into account weekends, leave/
holidays and sick-leave, a minimum of seven
full-time nurses is required for a small treatment
clinic. The costs of heroin itself were relatively
low, at £1,200 per person per year.
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What might it cost to prescribe heroin in the
UK?
The additional cost of prescribing heroin over
the standard treatment – methadone –
comprises two components, the additional price
of the drug and the additional cost of
supervised consumption. Current drug costs
could be misleading if heroin provision were
expanded. In the UK, heroin is available from a
sole supplier. The Department of Health could
negotiate a better price from the manufacturer.
Heroin is not covered by patent, there are no
pharmaceutical research costs to recoup and it is
derived from a plant product that is itself cheap
(see Table 7).
Is it cost-beneficial?
The Swiss trial suggests that the benefits of
heroin on prescription outweigh the treatment
costs. For every franc invested, there was a
benefit of CHF1.75. However, as cost data were
easy to obtain and benefits were often
estimated, it considers that the programme
might have a higher cost benefit ratio of
between three and five. The cost of prescribing
heroin is counterbalanced by savings for the
health sector in general (decrease in medical
and hospital costs), as well as the criminal
justice and employment sectors. Findings from
the Swiss trial show that the number of offences
committed while receiving heroin decreased
leading to a reduction in crime rates. In turn,
this led to cost savings to criminal justice (fewer
judges, policemen and prison wardens were
required). The number of days in employment
increased while receiving a prescription for
heroin, leading to an increase in the amount of
productivity and wages received.
It is uncertain if it is more cost-effective than
methadone
There are no data on comparative cost-
effectiveness of heroin compared to methadone.
But, at an estimated cost of £7,717–£9,691 per
patient per annum compared to £2,800 for
methadone (excluding supervised
consumption), its advantages need to outweigh
the additional cost.
Table 7  Estimated annual cost of prescribing heroin per patient in the UK
Cost Per annum (£)
Capital and revenue buildings and land, equipment, staff,
supplies and services, site and agency overheads)1 1,872
Supervised consumption for first 3 months2 987–2,961*
Drug costs – assuming 175 mg per day 4,858
Total 7,717–9,691
Notes:
1 Netten and Curtis (2001)
2 Strang et al. (2000)
* Lower cost based on cost of supervising one injection of methadone a day; upper cost inflated pro-




The evidence base is relatively weak – with only
a few studies, and only four with control groups
for comparison. Therefore, only cautious
conclusions can be drawn about the merits of
prescribing heroin.
That said, it appears that prescribing heroin
is feasible in specialist clinical settings, that it
succeeds in retaining people in treatment and
that there are health and social gains. Patients
improve in most areas – physical and mental
health are noticeably better, illicit drug use and
crime are reduced, and employment increases.
But problems are not eliminated. Individual
benefits have been identified in most studies,
but there are no data on community impact (e.g.
the overall effect on crime and drug scenes).
This evidence is based on information about
long-term injectors and smokers for whom other
treatments have failed. There are no data on
what benefits would be found with other
patients, or about who would most benefit from
this treatment. There is no information on
whether the availability of a heroin treatment
attracts more people into treatment.
Prescribing heroin costs more than
prescribing methadone but it may be cost-
beneficial. However, it is unclear whether the
benefits of prescribing heroin outweigh the
additional costs when compared with
methadone.
A cautious assessment of the evidence
suggests that heroin is potentially an effective
treatment for some patients, but that this has not
yet been conclusively proven. Any expansion in
the provision of heroin prescribing must be
monitored and properly evaluated. The
government interest in expanding the provision
of heroin provides the opportunity to do this.
We have lost many opportunities to conduct
research on the effectiveness of prescribing
heroin in the UK – and it would be unfortunate
if we lost this new chance to do some definitive
work.
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plan
The current prescribing of heroin in the UK is
inconsistent and arbitrary. In spite of 80 years of
prescribing heroin to opiate addicts, no
consensus exists about who should be treated
and what benefits heroin prescribing might be
expected to achieve.
Despite the UK being one of the few
countries where heroin can be prescribed for the
treatment of opiate dependence, most doctors
don’t want to prescribe it. Few people
dependent on illicit heroin receive prescriptions
for it. Even doctors with Home Office licences to
prescribe heroin are, with a few exceptions,
reluctant to initiate prescriptions for heroin. For
dependent heroin users, the odds of getting a
prescription for heroin are low, and are often
determined by place of residence and the
inclinations of the doctor providing treatment at
the local drug service.
Furthermore, heroin as a treatment for opiate
dependence has not been properly researched or
evaluated in the UK; as the Audit Commission
(2002) concluded, the current provision of
heroin has grown up in a haphazard way and is
not part of any plan. In the past, this typically
British way of muddling along may have had
the merits of flexibility and innovation, and of
being a welcome counterbalance to an over-
bureaucratised health service. But the current
muddle reflects a lack of vision and direction. In
the twenty-first century, both heroin-dependent
patients and the public deserve high quality,
accessible and equitable drug treatment
services. The costs to society – both in terms of
public health and crime – are too great to ignore
this challenge.
The Updated Drug Strategy aims to improve
access to prescribed heroin for those with a
clinical need for it (Home Office, 2002, p. 11).
While the willingness of the government to
favourably consider the idea of prescribing
heroin is to be welcomed, a major stumbling
block is the lack of evidence of what might
constitute ‘clinical need’. It appears that doctors
have one goal of treatment (the health of the
drug user and their freedom from addiction)
and policy makers hold different goals (the
needs of society as a whole), hence their interest
5 Challenges for expanding heroin
prescribing
If heroin prescribing were to increase, how could this be done?
This chapter:
• shows that heroin prescribing in the UK lacks a clear plan
• examines who would want to prescribe it, what kinds of heroin would be prescribed and how it
would be prescribed
• argues that it is essential that any government plan to increase heroin prescribing has to be
accompanied by rigorous evaluation and assessment.
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in providing heroin as a risk-reduction strategy
and more recently to reduce crime. In order to
persuade the doctors to prescribe heroin, the
policy makers need to make a strong argument
for its clinical efficacy. Because of the dearth of
research in this field, the questions of who
might benefit, and in which circumstances,
remain unanswered. Without this evidence,
doctors may remain reluctant to prescribe
heroin.
Unless there is a clear strategy for increasing
the provision of heroin across the UK to ensure
that all eligible drug users have access to this
treatment, the inconsistent and haphazard
nature of prescribing will continue. If heroin on
prescription is to be made available to all those
who need it and if it is to play a role in the way
we treat drug problems, it has to be done well.
That means that it has to be introduced, where
now unavailable, and expanded, where
currently available, in a systematic manner, and
subject to scrutiny and evaluation.
There must be some clear plan of action. This
should include objectives that specify:
• the aims of prescribing heroin (what it
hopes to achieve)
• patient eligibility criteria (those who are
most likely to be in need and to benefit)
• outcome criteria against which such a
plan can be assessed – objectively
verifiable indicators that indicate whether
the plan is on track.
Clinical guidance: a necessary but
insufficient response
The Home Office has indicated that the current
guidance on prescribing heroin may be too
restrictive (Department of Health, 1999).
Therefore, the National Treatment Agency has
developed new clinical guidance on heroin
prescribing (National Treatment Agency, 2003).
The new guidance was informed by an expert
group including clinicians, researchers, service
users and policy advisers. The expert group
reached some consensus about good practice
based on current experience and the limited
evidence from outside the UK.
The guidance – which covers both injectable
heroin and injectable methadone – states that
‘The prescribing of injectable substitute opioid
drugs for maintenance may be beneficial for a
minority of heroin misusers’ (p. 3). It gives
guarded endorsement to prescribing heroin,
within a range of stepped prescribing options,
where optimised oral methadone maintenance
treatment should be the treatment for the
majority of heroin users. It states the first
priority is to improve the effectiveness of oral
methadone maintenance.
The NTA recommends that injectable heroin
or methadone should be considered only for a
minority of patients who do not respond to
‘optimised’ oral methadone maintenance. The
eligibility criteria suggest that heroin should be
prescribed as a treatment of last resort – patients
should have a history of more than three years of
heroin dependence and regular daily injecting,
have previously received optimised oral
methadone treatment for at least six months, and
have failed to respond to this treatment.
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The NTA states that new maintenance
prescribing of injectable drugs should only be
undertaken in accordance with eight principles.
Pilot centres for new types of injectable
maintenance drug treatment will be established
in line with these eight principles.
National Treatment Agency for Substance Misuse – principles for prescribing heroin and
injectable methadone
1 Drug treatment comprises a range of treatment modalities which should be woven together
to form integrated packages of care for individual patients.
2 Substitute prescribing alone does not constitute drug treatment. Substitute prescribing
requires assessment and planned care, usually with psycho-social interventions. It is one
element within wider packages of planned and integrated drug treatment.
3 A range of substitute prescribing options are required. Patients should be offered options in a
series of steps, including optimised oral methadone, before injectable methadone or
injectable heroin maintenance treatment is tried.
4 Injectable maintenance options should be offered in areas that can provide optimised oral
methadone maintenance treatment including adequate doses, supervised consumption and
psycho-social interventions.
5 Injectable and oral substitute prescribing must be supported by locally commissioned and
provided mechanisms for supervised consumption.
6 Injectable maintenance treatment is likely to be long-term treatment with long-term resource
implications. Clinicians should consider the long-term implications for patients and services.
7 Specialist levels of clinical competence are required to prescribe injectable substitute drugs.
Heroin prescribing also requires a Home Office license.
8 The skills of the clinician should be matched with good local systems of clinical governance,
supervised consumption and access to a range of other drug treatment modalities.
There is need for further work around identifying the most effective models of delivery.
(Summaried from: National Treatment Agency, 2003, p. 4)
The guidance does not cover non-injectable
forms of heroin, does not give guidance on
doses, and does not advise on the choice




Guidance is necessary, but, on its own, it is
insufficient because it is inevitably constrained
by the current lack of a good UK evidence base.
Moreover, it is, in any case, a poor lever for
change, having teeth only when bringing
aberrant prescribers into line. It is unlikely in
itself to encourage more doctors to prescribe.
Practical issues
Who might be prescribed heroin?
If heroin is to be prescribed to heroin users with
a clinical need, there need to be agreed patient
eligibility criteria and an agreed rationale as to
why and how they would benefit from receiving
such a prescription.
The current state of evidence does not help
answer the question ‘how many people might
have a clinical need for heroin?’. A needs
analysis should be undertaken to assess how
many people might benefit from a heroin
prescription under different eligibility criteria.
There is general consensus (as indicated by
the NTA) that heroin could be prescribed as a
‘treatment of last resort’ for those who do not
respond sufficiently well to other treatments, i.e.
problem heroin users with long injecting
careers, who have tried and not significantly
improved with other treatments such as oral
methadone and who will not stop injecting. To
date, all the research evidence is based on this
group of heroin users.
The pathway into heroin treatment could be
by transferring on to heroin those currently
receiving other treatment (e.g. oral or injectable
methadone) but who have failed to obtain
benefits from it, or by attracting back into
treatment those who have tried previous
treatments and not been significantly helped by
them.
Consideration could also be given to heroin
being prescribed in order to attract heroin users
into treatment for the first time. There is a
considerable time lapse between developing a
drug problem and seeking help, and there are
heroin users who have never presented for or
received treatment but who have a long history
of illicit heroin use and/or injecting. Prescribing
heroin might attract people into treatment for
the first time sooner than hitherto. It would be a
‘bait’ to establish first contact – and could
perhaps be used as a prelude to other
treatments (e.g. methadone). So far, however,
there is little support for this idea of a ‘treatment
of first resort’ among doctors in the UK. To date,
there is no research evidence about the potential
efficacy of this treatment for this group of heroin
users. However, the heroin trial currently being
conducted in Germany (Krausz, 2001) plans to
include heroin users who have been using
heroin for many years but who have not had
any previous treatment experience.
Who would prescribe it?
How could the numbers of patients receiving a
prescription for heroin be increased as part of a
monitored and evaluated strategy? This is likely
to present a human resources problem.
There are about 85,000 doctors practising in
the NHS in the UK, of which about 30,000 are
general practitioners. There are 2,861 consultant
psychiatrists, but, in 1999, there were only about
90 consultants in the UK with a primary or
secondary interest in substance misuse (Royal
College of Psychiatrists, 2002).
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In 2000, only 70 doctors had licences to
prescribe heroin, and only 46 prescribed heroin.
Our survey (Metrebian et al., 2002) found that
many doctors with licences were reluctant to
prescribe heroin, and many who were eligible
for a licence did not want one.
There are several options.
• Increase the numbers being treated by those
doctors who currently prescribe. But, as we
have shown, only half of these have
initiated prescriptions for heroin, and the
rest are reluctant to prescribe to new
patients and restrict themselves to
prescribing to those whose heroin regime
was initiated by others. More of these
doctors would need to agree to initiate
prescriptions for heroin. Geographical
variations in prescribing would continue
to persist.
• Increase the number of doctors with licences
who actually prescribe heroin. Only 46 out of
70 licensed doctors were prescribing
heroin in 2000. But, given their current
reluctance to prescribe heroin, it is
unclear what would persuade them to
change.
• Increase the number of consultant
psychiatrists who can prescribe heroin, which
would require expanding the number of
psychiatrists with a specialist interest in
substance misuse.
• Extend the licensing system to include
general practitioners. About 50 per cent of
GPs in England have seen a drug user in
the last month and 25 per cent have
prescribed methadone (Home Affairs
Committee, 2002a, p. 50). The Home
Office has indicated that it sees the
expansion of heroin prescribing occurring
through the expansion of the number of
doctors licensed to prescribe it, including
general practitioners (Home Affairs
Committee, 2002a). However, a problem
with this option is that the Royal College
of General Practitioners has already come
out against GPs doing this.
Doctors clearly have the right not to deliver
treatments on ethical or religious grounds: the
problem for equity of NHS provision arises
when doctors have a local monopoly of
treatment – as is usually the case in addiction
services. Mechanisms would need to be found
for the NHS through the National Treatment
Agency to ensure that heroin prescribing is one
of the treatments available in each area.
The Dutch heroin trial – the need for
training
Supervised co-prescription of heroin to chronic,
treatment-resistant heroin-dependent patients is a
complex treatment with potent pharmacological
compounds in patients with high levels of
somatic and psychiatric co-morbidity. Therefore, a
state-of-the-art treatment requires adequate
medical and addiction training, and an adequate
medical staffing in terms of both physicians and
nurses. In addition, adequate drug accountability
has to be secured. Finally, adequate possibilities
for counselling, psychotherapy and rehabilitation
should be available.
(van den Brink et al., 2002, p. 154)
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How would prescribing it be monitored?
There are currently no monitoring mechanisms
to generate useful information on current
prescribing of heroin. Expanding the provision
of heroin prescribing would need to be
accompanied by routine information gathering
on who is prescribing what to whom, perhaps
as part of a regulatory framework.
What kinds of heroin would be prescribed?
The debate about heroin prescribing in the UK
has been confined mainly to injectable heroin.
But nearly half of the drug users coming to
treatment do not inject. It seems perverse to
discuss making heroin available only to
injectors, given that the risks to health of using
heroin are greater when heroin is injected than
when smoked. There are also good grounds for
encouraging current smokers not to switch to
injecting, and to persuade current injectors to
stop injecting and switch back to smoking
heroin.
Individual and public health gains might
therefore come from prescribing smokeable and
inhalable heroin. But how could
pharmaceutical-grade smokeable heroin be
made available and consumed? Some doctors
prescribe heroin reefers using diamorphine
hydrochloride dissolved and injected into
cigarettes. These are inefficient with low bio-
availability of heroin. In the Dutch trials,
powdered heroin was offered for smoking
(‘chasing’) using diamorphine base mixed with
caffeine. This was found to be feasible and
effective. A further option is to try other
delivery systems such as an aerosol inhalation.
Daily doses prescribed in the UK are lower
than those in the Dutch and Swiss trials. This
may reflect both a reluctance to prescribe and
the high cost of the drug. Studies need to be
conducted so as to arrive at suitable doses.
Current evidence indicates that methadone
would also need to be prescribed in tandem
with heroin in order to prevent night-time
withdrawal.
Should consumption be supervised?
The Department of Health recommends that
consumption of substitute drugs should be
supervised daily for at least the first three
months of treatment to ensure treatment
compliance, and reduce diversion and overdose.
Supervision is relatively easy with oral
medications such as methadone. Daily
consumption can be observed by clinic staff if
the drug is dispensed on site, or by a
community pharmacist. This might be
inconvenient for a patient in relation to
employment and travel, but the ingestion itself
takes only a few moments.
Supervising injecting or smoking is more
difficult. Both take longer, require privacy and,
in the case of smoking, the staff might inhale
slipstream smoke. In the Netherlands and
Switzerland, special injecting rooms were built
and, in the Netherlands, the smoking room had
lower air pressure than outside to prevent
escape of smoke. In addition to construction and
space costs, the main cost is the 30 minutes or so
of staff time for observing each patient, and the
fact that patients consuming heroin need to
come in two or three times a day. The facility
needs to be open for longer hours than would
be normal in a UK drug clinic, and possibly at
the weekends (unless weekends were exempted
from daily supervision). If one of the aims of
treatment is to facilitate a return to ‘normal life’,
the need for the patient to attend two or three
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times a day is likely to be a serious obstacle, at
least in the short term).
Illicit heroin is easily available and many
drug users are not coming forward for
treatment. Any provision of heroin prescribing
needs to be delivered with few barriers to
treatment to ensure it remains an attractive
treatment option that will catch the attention of
and retain drug users. Regular supervision of
injecting might be a barrier to treatment.
A vision and a strategy
Studies in other countries provide useful
information about heroin prescribing but, since
the treatment context is different, it is unclear
how far this can be applied to the UK situation.
It is ironic that undertaking such studies is
easier in Britain than in any other country and
yet these studies have not been conducted.
Heroin prescribing should not be expanded
in an ad hoc manner. Evaluating pilot centres
might provide some further evidence of
feasibility of different models of care, but will
not deliver evidence about effectiveness. The
priority must be for a multi-centre, randomised,
controlled trial comparing heroin against
standard treatment. The UK has a poor track
record in treatment research – in part, a
reflection of the overall under-funding of
research on drug problems. For every £995
spent on responding to drugs, only £5 is spent
on research. There can be little benefit from
expanding the provision of heroin unless it is
monitored and evaluated. We still need answers
to questions about who benefits, in what way, at
what cost and whether these benefits exceed
those of standard substitute treatment (oral
methadone).
Implementing this strategy will require clear
commitment. It will require a continuation of
political will – mainly from the Home Office,
clinical and commissioning guidance from the
National Treatment Agency, treatment resources
from the Home Office and the Department of
Health, the enthusiasm and support of the
medical profession, support from local Drug
Action Teams and commissioners. It will require
major research funding to ensure that it is
properly evaluated.
An increase in the provision of heroin and an
evaluation of the part it can play in treating
people with heroin problems is well overdue. It
would be a clear failure of vision if, ten years
ahead, we still have the same vague system and
the same unanswered questions about the
effectiveness of prescribing heroin.
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Studies in the UK
Stimson et al.
This study was based on a randomly selected
sample of one in three heroin users attending the
first London drug clinics and being prescribed
heroin in 1969 (Stimson and Ogborne, 1970;
Stimson and Oppenheimer, 1982). Heroin was
then the standard treatment for opiate
dependence. Patients were followed up at seven,
ten and 22 years. Heroin users’ lives and
addiction careers, their experiences at the drug
clinics and the operational problems of the
clinics were examined. Contrary to the belief that
heroin addicts were a homogeneous group, great
differences between them were found and these
characteristics were associated with treatment
outcome. A minority of patients were stable on
their heroin prescription. They suffered fewer
social and physical complications of addiction,
were more likely to be legally employed and to
avoid other drug users, and were less likely to
use illicit drugs or to be involved in any criminal
activity. The majority had more chaotic lifestyles.
They were often unemployed and had higher
involvement in crime, spent more time with
other drug users and used more illicit drugs. At
six years’ follow-up (Thorley et al., 1977), 51 per
cent were still in treatment, 40 per cent were
alive and not attending treatment and 9 per cent
were dead. One-third were still receiving a
prescription for heroin.
Hartnoll et al.
The first and only heroin trial in the UK was
conducted at a London drug dependence clinic
in the 1970s (Hartnoll et al., 1980). Ninety-six
opiate-dependent injecting drug users
requesting heroin were randomly allocated to
receive either injectable heroin or oral
methadone maintenance and followed up at 12
months. Heroin and methadone doses ranged
from 40 to 80 mg per day. Drug consumption
was not supervised. Almost all patients
receiving heroin continued to inject regularly
and the majority continued to obtain illicit
drugs, although usually in small quantities. The
majority remained in contact with other drug
users and were involved in drug-related
activities, although less intensively than before
they received heroin. Those receiving oral
methadone tended to move to one extreme or
another. They had a higher drop-out rate than
the heroin group, but they were more likely to
become abstinent or near abstinent. On the
other hand, those who continued to inject and
use drugs were obtaining larger quantities of
illicit opiates than those receiving heroin. The
methadone group either ceased drug-related
activities or were using lots of drugs and were
heavily involved in the drug scene. The authors
concluded that the results did not indicate a
clear overall superiority of either treatment.
Both had advantages and disadvantages. Oral
methadone discouraged illicit drug use but
there were a group of people for whom it failed
and they continued to be heavily involved in
drugs. Heroin encouraged continued drug use
and would lead to larger steadily accumulating
clinic populations.
McCusker and Davies
Similarly inconclusive results were found in a
case control study of 27 drug users receiving
injectable or smokeable heroin and 39 receiving
Appendix: Summary of studies of the
effectiveness of prescribing heroin
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oral methadone from drug clinics in the North
West of England (McCusker and Davies, 1996).
The two groups were matched for age, gender,
length of time using opiates and length of time
receiving their current treatment. The heroin
group were first interviewed an average of 11
months after first receiving their treatment and
the methadone group after nine months. Both
groups were interviewed again six months later.
The mean dose was 253 mg per day for heroin
and 72 mg per day for oral methadone. The
heroin group – compared with those on
methadone – were better retained in treatment,
used less illicit heroin, shared injecting
equipment less often, were less likely to be
involved in criminal behaviour, spent less
money on illicit drugs and had better
psychological health. The heroin group were
less likely to have abstinence as a treatment goal
and more likely to be using cocaine than the
methadone group. There were no significant
differences between the groups in their use of
illicit non-opiate drugs and physical health.
Metrebian et al.
In an observational study of prescribing heroin
at a West London drug clinic, 58 long-term
opiate-dependent drug injectors who had
previously tried and failed oral methadone
treatment were offered the choice to receive
either injectable heroin or injectable methadone.
They were followed up for 12 months
(Metrebian et al., 1998, 2001). One-third (21)
chose to receive methadone, the other two-
thirds (37) opting for heroin. Overall, 57 per cent
were retained in treatment at 12 months; with
the heroin group better retained in treatment
than the methadone group (59 vs. 48 per cent).
Significant reductions in illicit drug use,
criminal behaviour and improvements in health
and social status were found in the first three
months of treatment for both groups. These
improvements were sustained between three
and 12 months. Two subjects progressed to oral
methadone treatment and one became
abstinent. There was no significant difference in
treatment outcome between the heroin and
methadone group. The authors concluded that
prescribing injectable drugs was a feasible
treatment option. Drugs were dispensed at the
clinic daily, with weekend doses taken home for
the first few weeks and less frequently
thereafter. Patients were not able to inject on
site. To reduce the risk of diversion, subjects had
to return used ampoules and batch numbers




Between 1994 and 1996, a series of studies to
examine the effectiveness of prescribing
injectable and smokeable heroin, injectable
methadone and injectable morphine were
undertaken in Switzerland (Uchtenhagen et al.,
1996, 1997, 1999). The research was conducted
as a result of the concern for the high numbers
of dependent drug users in Switzerland and the
high prevalence of HIV infection. Switzerland
has a relatively well equipped and diversified
system of treatment for dependent heroin users
but a large group of dependent heroin users
were either not in contact with drug services or
had tried and failed them. The objectives of
these studies were to examine the effects of
these drugs on the health, social integration and
drug-related behaviour of long-term heroin-
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dependent drug users who had tried and failed
previous drug treatments. The studies included
two double-blind studies (so called because the
prescribed drug is not known to either the
patient or the doctor), two randomised studies
(where patients were randomly allocated to
treatments) and 11 studies where the patient
was allocated to treatment based on clinical
assessment and patient choice. Moreover, the
viability of prescribing heroin was studied at
three methadone out-patient drug clinics and
one prison.
The analysis of the effectiveness of heroin
was based on a cohort of 800 subjects receiving
heroin in a number of treatment centres
throughout Switzerland. (While this study was
technically not a trial – it did not randomise
patients to treatment and had no comparison
group – it has always been referred to as a trial.)
Heroin was dispensed three times a day, seven
days a week, from selected drug clinics for
supervised injection on site in designated
injecting rooms. The mean daily dose was 500
mg. Multidose ampoules containing 500 mg and
higher multidose ampoules of 10 g (10,000 mg)
were produced. Injecting equipment was
provided by the clinics in the injecting rooms.
Treatment involved a prescription for one of the
above drugs with psycho-social interventions
(counselling, social work, etc.).
At 18 months, 69 per cent of subjects were
retained in treatment and the mortality rate was
1 per cent per year. There were significant
reductions in illicit drug use and criminal
behaviour, and significant improvements in
physical and psychological health, and in social
functioning. At 18 months, illicit heroin use
reduced from nearly all subjects reporting daily
use to 26 per cent reporting daily use. Cocaine
use reduced from 85 per cent using at the start
of the trial, to 59 per cent at 18 months. At 18
months, criminal behaviour reduced from 69
per cent reporting income from illicit sources to
10 per cent. Police records and official crime
statistics verified self-reported criminal activity.
Health improvements included general and
nutritional status and injection-related skin
diseases, and psychological improvements were
most notable in the areas of depressive states
and anxiety states and delusional disorders.
There was a lack of control group (receiving
oral methadone) for comparison. Therefore,
even after this large study, it is not possible to
conclusively answer the question of whether
prescribing heroin to long-term dependent drug
users is more effective than prescribing oral
methadone. The researchers recommended a
continuation of this treatment for ‘chronic and
marginalised heroin addicts who failed in other
treatment modalities’ and that ‘similar
conditions and safety controls as established for
the study should be applied’ (Uchtenhagen et
al., 1999). Heroin addicts have continued to be
prescribed heroin in Switzerland and
researchers have continued to collect data on
their progress (Rehm et al., 2001).
Perneger et al.
In a further study, in Geneva, 46 long-term
dependent heroin users were randomised to
either receive a prescription for heroin or were
put on a waiting list where most received oral
methadone (Perneger et al., 1998). After six
months, the heroin group showed significant
reductions in illicit heroin use and criminal
behaviour, and significant improvements in
psychological health and social functioning




van den Brink et al.
The Dutch heroin trial started in 1998 and was
completed at the end of 2001. The primary
objective was to evaluate the beneficial and
harmful effects of maintenance treatment with
oral methadone when patients were
additionally prescribed heroin. Hence, the study
is accurately described as a study of ‘heroin co-
prescription’ – the patients continued to receive
methadone and in addition were given legal
heroin. Those in the heroin arm of the trial were
compared with patients who received the
standard maintenance treatment of oral
methadone. Two randomised controlled trials
were conducted, comparing (1) the co-
prescription of inhalable heroin with oral
methadone and (2) comparing the co-
prescription of injectable heroin with oral
methadone. This was a multicentre trial in eight
centres in six cities. Patients in trial (1) were
randomly allocated to receive (a) oral
methadone for 12 months, or (b) methadone and
inhalable heroin for 12 months, or (c)
methadone for six months followed by
methadone and inhalable heroin for six months.
Patients in trial (2) were randomly allocated to
either (a) methadone for 12 months or (b)
methadone and injectable heroin for 12 months.
All groups were followed up for a further six
months. The consumption of heroin was
supervised three times a day at the drug clinic.
The mean dose of heroin prescribed was
between 530 and 560 mg per day.
Heroin was seen as a treatment of last resort
for a group of highly problematic heroin users
(mainly smokers) within the methadone
population. This trial recruited patients who
were already in methadone treatment
programmes but who were doing badly, defined
as chronic, treatment-resistant heroin addicts.
The impact of the medical co-prescription of
heroin was evaluated in terms of (a)
improvement in the physical and mental status
of the patients, (b) improvement in their social
integration and social functioning, and (c)
changes in their illicit drug use. Further study
objectives included (a) a comparison of the
effects of co-prescribed heroin given for six
months’ and 12 months’ duration, and (b) an
evaluation of the effects of the discontinuation
of co-prescribed heroin after six and 12 months
of treatment with co-prescribed heroin.
The primary outcome measure was at least a
40 per cent improvement in physical health,
mental health or social functioning, and no
increase in substance use and no deterioration
of 40 per cent or more in any area. Patients with
this outcome were called ‘responders’.
At 12 months, in Trial 1, 87 per cent of the
methadone group had completed treatment
compared to 68 per cent of the co-prescribed
inhalable heroin group. In Trial 2, 85 per cent of
the methadone group completed treatment
compared to 72 per cent of the co-prescribed
injectable heroin group. However, patients
receiving injectable heroin were able to switch to
receive inhalable heroin; 33 per cent made this
switch. After 12 months, 48 per cent of patients in
the co-prescribed inhalable heroin group were
‘responders’ compared to 25 per cent in the
methadone group. Similarly, 57 per cent of
patients in the co-prescribed injectable heroin
group were ‘responders’ compared to 32 per cent
in the methadone group. Two months after
discontinuation of the co-prescribed injectable or
inhalable heroin treatment, the majority of
‘responders’ had deteriorated considerably.
